Breaking News: BOLT latest news.

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	Bolt Biotherapeutics price target lowered to $13 from $16 at Stifel » 14:34 05/13/22 05/13 14:34 05/13/22 14:34 BOLT Bolt Biotherapeutics $1.51 / -0.04 (-2.58%) Stifel analyst Stephen… Stifel analyst Stephen Willey lowered the firm's price target on Bolt Biotherapeutics to $13 from $16 and keeps a Buy rating on the shares following the company's Q1 earnings report and corporate update. He believes investor perception of the longer-term opportunity for BDC-1001 will likely "remain appropriately muted" based on competitive dynamics in the treatment of HER2+ solid tumors and his reduced price target mostly reflects revised financing assumptions, Willey said. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BOLT Bolt Biotherapeutics $1.51 / -0.04 (-2.58%) 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial BOLT Bolt Biotherapeutics $1.51 / -0.04 (-2.58%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel BOLT Bolt Biotherapeutics $1.51 / -0.04 (-2.58%) 05/12/22 Bolt Biotherapeutics reports Q1 EPS (64c), consensus (72c) 03/30/22 Bolt Biotherapeutics reports Q4 EPS (73c), consensus (82c) BOLT Bolt Biotherapeutics $1.51 / -0.04 (-2.58%) 03/31/22 What You Missed On Wall Street This Morning 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 06/10/22 Bolt Biotherapeutics, Inc.
Earnings	Bolt Biotherapeutics reports Q1 EPS (64c), consensus (72c) » 16:31 05/12/22 05/12 16:31 05/12/22 16:31 BOLT Bolt Biotherapeutics $1.55 / +0.075 (+5.08%) Reports Q1 revenue $813K,… Reports Q1 revenue $813K, consensus $370K. "Our lead program, BDC-1001, for patients with HER2-expressing solid tumors is on track and we expect to complete both our monotherapy and combination dose escalation arms and select a recommended Phase 2 dose in the second half of 2022," said Randall C. Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "We continue to apply our expertise in myeloid biology to advance our diversified pipeline of novel Boltbody ISACs and our first-in-class Dectin-2 agonist antibody program. Our strong cash position and multiple collaborations with leading therapeutic antibody companies are expected to provide us with the funding to achieve key clinical milestones with our most promising candidates in a cash-efficient manner." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BOLT Bolt Biotherapeutics $1.55 / +0.075 (+5.08%) 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial BOLT Bolt Biotherapeutics $1.55 / +0.075 (+5.08%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel BOLT Bolt Biotherapeutics $1.55 / +0.075 (+5.08%) 03/30/22 Bolt Biotherapeutics reports Q4 EPS (73c), consensus (82c) BOLT Bolt Biotherapeutics $1.55 / +0.075 (+5.08%) 03/31/22 What You Missed On Wall Street This Morning 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 06/10/22 Bolt Biotherapeutics, Inc.

Over a month ago
On The Fly	What You Missed On Wall Street This Morning » 12:14 03/31/22 03/31 12:14 03/31/22 12:14 WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) , AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) , JPM JPMorgan $138.58 / -1.91 (-1.36%) , TPX Tempur Sealy $28.05 / -0.95 (-3.28%) , PATH UiPath $21.66 / -7.38 (-25.41%) , EXFY Expensify $16.27 / -2.365 (-12.69%) , AMD AMD $111.17 / -8.03 (-6.74%) , HPQ HP Inc. $36.74 / -2.095 (-5.39%) , DELL Dell Technologies $51.42 / -2.86 (-5.27%) , FIVE Five Below $162.17 / +1.65 (+1.03%) , COIN Coinbase $193.50 / -3.2 (-1.63%) , SNOW Snowflake $235.25 / +3.6 (+1.55%) , VIPS Vipshop $9.26 / +0.05 (+0.54%) , FLEX Flex $18.96 / +1.595 (+9.19%) , AMLX Amylyx $13.40 / -1.55 (-10.37%) , IQ iQIYI $4.64 / -0.405 (-8.03%) , BIDU Baidu $134.85 / -9.02 (-6.27%) , SHCR Sharecare $2.73 / -0.55 (-16.79%) , NNDM Nano Dimension $3.57 / -0.26 (-6.80%) , AAPL Apple $177.06 / -0.615 (-0.35%) , QCOM Qualcomm $154.02 / +1.295 (+0.85%) , FB Meta Platforms $224.95 / -2.82 (-1.24%) , F Ford $17.13 / -0.15 (-0.87%) , TSLA Tesla $1,097.57 / +3.66 (+0.33%) , MASI Masimo $148.79 / -6.28 (-4.05%) , VRRM Verra Mobility $16.57 / +0.89 (+5.68%) , NNOX Nano-X Imaging $10.98 / +1.55 (+16.44%) , DARE Dare Bioscience $1.55 / +0.09 (+6.16%) , BOLT Bolt Biotherapeutics $2.72 / -0.06 (-2.16%) Get caught up quickly on… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options WBA VRRM VIPS TSLA TPX SNOW SHCR QCOM PATH NNOX NNDM MASI JPM IQ HPQ FLEX FIVE FB F DELL DARE COIN BOLT BIDU AMZN AMLX AMD AAPL WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) 03/30/22 Florida announces $860M opioid settlement with CVS, Teva, Allergan 03/17/22 Walgreens Boots, VillageMD to expand primary care practices in New Hampshire 03/07/22 Walgreens, Labcorp offer at-home COVID PCR test collection kits at no cost 02/24/22 Target's Shipt announces launches with Walgreens and 7-Eleven VRRM Verra Mobility $16.57 / +0.89 (+5.68%) 03/08/22 Verra Mobility receives noncompliance notification from Nasdaq 03/04/22 Verra Mobility names Craig Conti as CFO, succeeding Patricia Chiodo 02/28/22 Verra Mobility files SEC form 12B-25, provides business update 02/07/22 Verra Mobility awarded contract renewal by New York City VIPS Vipshop $9.26 / +0.05 (+0.54%) 03/31/22 Vipshop announces $1B share repurchase program 02/23/22 Vipshop falls -10.9% 11/18/21 Vipshop falls -17.1% 11/18/21 Vipshop falls -13.4% TSLA Tesla $1,097.57 / +3.66 (+0.33%) 03/28/22 Tesla's head of AI Andrej Karpathy taking sabbatical 03/28/22 Tesla's Elon Musk considering building a new social media platform 03/28/22 Tesla's Elon Musk tests positive for Covid-19, 'almost no symptoms' 03/28/22 Tesla to ask investors to authorize additional shares to enable stock split TPX Tempur Sealy $28.05 / -0.95 (-3.28%) 02/22/22 Tempur Sealy falls -16.5% 02/22/22 Tempur Sealy falls -13.0% 02/22/22 Tempur Sealy falls -12.9% 02/22/22 Tempur Sealy increases quarterly dividend to 10c per share SNOW Snowflake $235.25 / +3.6 (+1.55%) 03/06/22 Fly Intel: Top five weekend stock stories 03/02/22 Snowflake sees Q1 operating margin at negative 2% 03/02/22 Snowflake drops 24% to $201.20 after mixed Q4 results, FY23 guidance SHCR Sharecare $2.73 / -0.55 (-16.79%) 01/27/22 Sharecare awarded three-year NCQA Population Health Program Accreditation 01/04/22 CareLinx by Sharecare selected as benefit program for 1.5M Medicare members 01/04/22 Sharecare announces leadership appointments 12/03/21 Sharecare's Unwinding Anxiety shown to decrease anxiety by 67% in trial QCOM Qualcomm $154.02 / +1.295 (+0.85%) 03/24/22 Veoneer announces merger closing on April 1 03/23/22 ParkerVision announces district court ruling in favor of Qualcomm 03/22/22 Qualcomm, Square Enix partner over extended reality experiences 03/11/22 Orlando Court grants Qualcomm motion blocking ParkerVision presentation PATH UiPath $21.66 / -7.38 (-25.41%) 03/31/22 UiPath falls -24.4% 03/31/22 UiPath falls -22.2% 03/31/22 UiPath falls -19.1% 03/30/22 UiPath falls 23% to $22.30 after Q4 results and below-consensus revenue outlook NNOX Nano-X Imaging $10.98 / +1.55 (+16.44%) 01/11/22 AMA issues Nanox Category III CPT code for cardiac imaging solution 12/20/21 Nano-X's Zebra Medical Vision secures 510k FDA clearance for HealthPPT 10/29/21 Nano-X Imaging enters agreement to deploy 350 Nanox systems in South America NNDM Nano Dimension $3.57 / -0.26 (-6.80%) 02/15/22 Nano Dimension appoints Igal Rotem to board of directors 02/02/22 Nano Dimension's Global Inkjet Systems to present at InPrint Munich 01/24/22 Nano Dimension establishes AME NanoLab Facility with TTM Technologies 01/10/22 Nano Dimension develops nano-particle conductive ink with XTPL MASI Masimo $148.79 / -6.28 (-4.05%) 03/30/22 Masimo reports preliminary Q1 product revenue $285M-$315M 02/28/22 Masimo gets FDA clearance of pediatric indication for SedLine monitoring 02/16/22 Masimo trading resumes 02/16/22 Masimo trading halted, volatility trading pause JPM JPMorgan $138.58 / -1.91 (-1.36%) 03/28/22 Chase launches new saver account for UK customers 03/20/22 Fly Intel: Top five weekend stock stories 03/16/22 Founding member banks see Versana syndicated loan platform launch this year IQ iQIYI $4.64 / -0.405 (-8.03%) 03/31/22 iQIYI provides update on status under HFCAA 03/30/22 iQIYI added to SEC provisional list of companies under HFCAA 01/26/22 iQIYI curates content for Chinese New Year holiday 01/25/22 iQIYI announces CFO Xiaodong Wang retires, Jun Wang to succeed HPQ HP Inc. $36.74 / -2.095 (-5.39%) 03/31/22 HP Inc. announces collaboration with Legor Group 03/28/22 HP Inc. to acquire Poly in all-cash transaction for $40 per share 02/23/22 HP Inc. introduces HP LaserJet Tank MFP 2600s 02/18/22 Intel names Christoph Schell as Chief Commercial Officer FLEX Flex $18.96 / +1.595 (+9.19%) 02/02/22 Flex to sell $500M of convertible preferred equity in Nextracker to TPG Rise 01/26/22 Flex jumps 6% to $16.76 after Q3 results, FY22 guidance top estimates 11/08/21 Flex names Cameron Carr as Chief Strategy Officer 10/19/21 Bertram Capital exits Anord Mardix with sale to Flex FIVE Five Below $162.17 / +1.65 (+1.03%) 03/30/22 Five Below expects to triple store count to 3,500+ by end of 2030 01/10/22 Five Below reports holiday period SSS up 7.7% 12/21/21 Five Below raises over $8M for charitable partners in 2021 12/01/21 Five Below jumps 9.6% to $207.40 after Q3 earnings beat, resumed FY21 guidance FB Meta Platforms $224.95 / -2.82 (-1.24%) 03/30/22 Meta says Wendy's launching virtual space in Horizon Worlds on April 2 03/30/22 Meta Platforms to create up to 2,500 jobs with Canadian engineering hub 03/28/22 Instagram debuts updates to aid 'social movements,' take action, raise funds 03/23/22 NFL, StatusPRO to develop NFL-licensed VR game for Meta Quest, PSVR F Ford $17.13 / -0.15 (-0.87%) 03/24/22 Ford recalls nearly 200,000 pickups and SUVs over brake issue 03/21/22 Ford confirms F-150 Lightning final EPA-estimated range for all models 03/17/22 EU passenger car registrations down 6.7% in February 03/16/22 S&P Global Mobility sees Ukraine repercussions placing 2.6M vehicles at risk DELL Dell Technologies $51.42 / -2.86 (-5.27%) 02/24/22 Dell Technologies initiates quarterly dividend of 33c per share 02/14/22 Elliott buys Switch, exits Public Storage in Q4 01/02/22 Fly Intel: Top five weekend stock stories 11/23/21 HP Enterprise, Dell, IBM and others to compete for orders on $1.6B Army contract DARE Dare Bioscience $1.55 / +0.09 (+6.16%) 03/31/22 Dare Bioscience annouces key portfolio objectives 03/31/22 Dare gets $10M upfront from Organon for licensing rights to XACIATO for BV 12/07/21 Dare Bioscience Inc trading resumes 12/07/21 Dare announces FDA approval of XACIATO vaginal gel for bacterial vaginosis COIN Coinbase $193.50 / -3.2 (-1.63%) 03/30/22 Cathie Wood's ARK Investment bought 96.6K shares of Coinbase today 03/29/22 Cathie Wood's ARK Investment bought 288.2K shares of Coinbase today 03/28/22 Cathie Wood's ARK Investment bought 62.9K shares of Coinbase today 03/24/22 Alviere partners with Coinbase Prime for crypto services for The HIVE BOLT Bolt Biotherapeutics $2.72 / -0.06 (-2.16%) 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial BIDU Baidu $134.85 / -9.02 (-6.27%) 03/31/22 Baidu provides update on status under HFCAA 03/30/22 Baidu added to SEC provisional list of companies under HFCAA 03/04/22 Chindata appoints Qian Xiao as president, Xinyue Fan as COO 02/17/22 Baidu brings Apollo Go robotaxi service to downtown Shenzhen AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) 03/31/22 Chase enters multi-year extension with Amazon for Prime Rewards Visa credit card 03/31/22 Dynatrace expands partnership with Amazon Web Services 03/29/22 Snowflake extends relationship with AWS 03/29/22 Amazon announces U.S. availability of Amazon Glow AMLX Amylyx $13.40 / -1.55 (-10.37%) 03/31/22 Amylyx falls 20% to $12.00 per share after resumption of trade 03/31/22 Amylyx to resume trading at 07:05ET 03/30/22 FDA AdCom votes 4-yes, 6-no on efficacy of Amylyx's AMX0035 in ALS 03/30/22 Amylyx trading halted amid FDA Advisory Committee meeting on AMX0035 AMD AMD $111.17 / -8.03 (-6.74%) 03/22/22 AMD announces availability of AMD Instinct ecosystem 03/21/22 AMD announces 3rd Gen AMD EPYC processors with AMD 3D V-Cache tech 03/17/22 AMD announces AMD Software: Adrenalin Edition 2022 release 03/15/22 AMD announces availability of AMD Ryzen 7 5800X3D processor AAPL Apple $177.06 / -0.615 (-0.35%) 03/30/22 Apple says changes show commitment to legal obligations in Netherlands 03/30/22 CoreCard drops after report says Apple looks to bring finance services in-house 03/30/22 Apple announces $50M Supplier Employee Development Fund 03/28/22 Apple adjusts compliance proposal with requirements set by Netherlands' ACM WBA AMZN JPM TPX PATH EXFY AMD HPQ DELL FIVE COIN SNOW VIPS FLEX AMLX IQ BIDU SHCR NNDM AAPL QCOM FB F TSLA MASI VRRM NNOX DARE BOLT WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) 01/10/22 Mizuho Walgreens Boots Alliance price target raised to $56 from $51 at Mizuho 12/22/21 UBS Walgreens Boots Alliance price target raised to $52 from $50 at UBS 12/22/21 Baird Walgreens Boots Alliance price target raised to $70 from $68 at Baird 12/17/21 Morgan Stanley Walgreens Boots Alliance downgraded to Underweight at Morgan Stanley AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) 03/29/22 Exane BNP Paribas Amazon.com initiated with an Underperform at Exane BNP Paribas 03/28/22 Wedbush Apple makes history, wins Oscar for Best Picture with CODA, says Wedbush 03/25/22 Evercore ISI Evercore highlights 'four underappreciated elements' of Amazon story 03/22/22 Argus eBay price target lowered to $69 from $88 at Argus JPM JPMorgan $138.58 / -1.91 (-1.36%) 03/28/22 Morgan Stanley JPMorgan price target lowered to $161 from $170 at Morgan Stanley 02/14/22 Jefferies JPMorgan cut to Hold at Jefferies amid bank rating adjustments 02/14/22 Jefferies JPMorgan downgraded to Hold from Buy at Jefferies 01/18/22 UBS JPMorgan price target lowered to $197 from $210 at UBS TPX Tempur Sealy $28.05 / -0.95 (-3.28%) 03/30/22 Truist Tempur Sealy price target lowered to $37 from $45 at Truist 02/23/22 Loop Capital Tempur Sealy price target lowered to $35 from $40 at Loop Capital 02/23/22 KeyBanc Tempur Sealy price target lowered to $46 from $55 at KeyBanc 02/23/22 Wedbush Tempur Sealy price target lowered to $40 from $55 at Wedbush PATH UiPath $21.66 / -7.38 (-25.41%) 03/31/22 RBC Capital UiPath price target lowered to $32 from $37 at RBC Capital 03/31/22 BMO Capital UiPath price target lowered to $29 from $52 at BMO Capital 03/31/22 Truist UiPath price target lowered to $55 from $75 at Truist 03/31/22 Needham UiPath price target lowered to $40 from $85 at Needham EXFY Expensify $16.27 / -2.365 (-12.69%) 03/31/22 Loop Capital Expensify price target lowered to $17 from $22 at Loop Capital 03/31/22 JMP Securities Expensify price target lowered to $26 from $44 at JMP Securities 03/31/22 Citi Expensify price target lowered to $27 from $35 at Citi 03/31/22 Piper Sandler Expensify price target lowered to $25 from $45 at Piper Sandler AMD AMD $111.17 / -8.03 (-6.74%) 03/31/22 Barclays AMD downgraded to Equal Weight from Overweight at Barclays 03/27/22 Goldman Sachs AMD downgraded to Buy from Conviction Buy at Goldman Sachs 03/25/22 BofA BofA tactically most constructive on 'MANGO' stocks in U.S. Semiconductors 02/22/22 Bernstein Bernstein upgrades AMD to Outperform with $150 price target HPQ HP Inc. $36.74 / -2.095 (-5.39%) 03/31/22 Barclays HP Inc. price target lowered to $29 from $30 at Barclays 03/31/22 Morgan Stanley HP Inc. downgraded to Underweight from Equal Weight at Morgan Stanley 03/29/22 Morgan Stanley HP rationale for Poly deal 'appears compelling,' says Morgan Stanley 03/29/22 Deutsche Bank HP acquisition 'not cheap' for business struggling to grow, says Deutsche Bank DELL Dell Technologies $51.42 / -2.86 (-5.27%) 03/31/22 Barclays Dell Technologies price target lowered to $53 from $54 at Barclays 03/31/22 Morgan Stanley Dell Technologies downgraded to Equal Weight from Overweight at Morgan Stanley 03/08/22 Evercore ISI Dell Technologies upgraded to Outperform from In Line at Evercore ISI 02/25/22 Morgan Stanley Dell Technologies price target lowered to $66 from $68 at Morgan Stanley FIVE Five Below $162.17 / +1.65 (+1.03%) 03/31/22 Craig-Hallum Five Below price target lowered to $230 from $240 at Craig-Hallum 03/31/22 Truist Five Below price target lowered to $205 from $214 at Truist 03/31/22 Deutsche Bank Five Below price target raised to $284 from $276 at Deutsche Bank 03/31/22 Loop Capital Five Below price target lowered to $165 from $210 at Loop Capital COIN Coinbase $193.50 / -3.2 (-1.63%) 03/30/22 US Tiger Coinbase initiated with a Sell at US Tiger 03/22/22 Citi Coinbase price target lowered to $275 from $300 at Citi 02/28/22 Compass Point Coinbase price target lowered to $200 from $325 at Compass Point 02/25/22 Needham Coinbase price target lowered to $360 from $420 at Needham SNOW Snowflake $235.25 / +3.6 (+1.55%) 03/31/22 Atlantic Equities Atlantic starts 'priced for perfection' Snowflake with Neutral 03/31/22 Atlantic Equities Snowflake initiated with a Neutral at Atlantic Equities 03/29/22 Exane BNP Paribas Snowflake downgraded to Underperform from Neutral at Exane BNP Paribas 03/24/22 Truist Snowflake price target lowered to $350 from $400 at Truist VIPS Vipshop $9.26 / +0.05 (+0.54%) 03/14/22 JPMorgan Vipshop price target lowered to $7 from $9 at JPMorgan 03/07/22 Morgan Stanley JD.com price target lowered to $85 from $98 at Morgan Stanley 02/24/22 Morgan Stanley Vipshop downgraded to Equal Weight from Overweight at Morgan Stanley 01/03/22 CLSA Vipshop price target lowered to $10 from $11.80 at CLSA FLEX Flex $18.96 / +1.595 (+9.19%) 01/27/22 Craig-Hallum Flex price target lowered to $25 from $31 at Craig-Hallum 05/25/21 Stifel Plexus warning may be signal that supply constraints will worsen, says Stifel 05/07/21 Citi Flex price target raised to $25 from $22 at Citi 05/06/21 Cross Research Cross Research upgrades Flex to Buy after 'strong' Q4 AMLX Amylyx $13.40 / -1.55 (-10.37%) 03/31/22 H.C. Wainwright Amylyx approval odds unchanged with panel vote, says H.C. Wainwright 03/29/22 H.C. Wainwright Patient advocacy, data favor Amylyx into panel vote, says H.C. Wainwright 03/28/22 Jefferies Reata drop on Amylyx docs an opportunity to accumulate shares, says Jefferies 03/28/22 Citi Reata selloff following Amylyx briefing docs 'overdone,' says Citi IQ iQIYI $4.64 / -0.405 (-8.03%) 03/14/22 JPMorgan iQIYI downgraded to Underweight from Overweight at JPMorgan 03/02/22 JPMorgan iQIYI upgraded to Overweight from Neutral at JPMorgan 01/14/22 HSBC iQIYI price target lowered to $4.80 from $8.10 at HSBC 01/10/22 OTR Global iQIYI ad business view downgraded to Negative from Mixed at OTR Global BIDU Baidu $134.85 / -9.02 (-6.27%) 03/14/22 JPMorgan Baidu double downgraded to Underweight at JPMorgan amid sector-wide selloff 03/14/22 JPMorgan Baidu downgraded to Underweight from Overweight at JPMorgan 03/03/22 Susquehanna Baidu price target raised to $200 from $175 at Susquehanna 03/02/22 China Renaissance Baidu price target raised to $228 from $215 at China Renaissance SHCR Sharecare $2.73 / -0.55 (-16.79%) 02/11/22 Goldman Sachs Sharecare initiated with a Neutral at Goldman Sachs 01/18/22 BTIG BTIG would expect Sharecare to raise 2022 guidance along with Q4 report 01/04/22 BTIG Sharecare's announcements today 'significant positives,' says BTIG 11/24/21 BTIG Sharecare 'offers excelling buying opportunity', says BTIG NNDM Nano Dimension $3.57 / -0.26 (-6.80%) AAPL Apple $177.06 / -0.615 (-0.35%) 03/31/22 BTIG CoreCard weakness on report of Apple processing plans looks overdone, says BTIG 03/30/22 BofA Apple's lower trade-in prices imply strong demand, says BofA 03/28/22 Morgan Stanley Apple subscription offering can increase spend per user, says Morgan Stanley QCOM Qualcomm $154.02 / +1.295 (+0.85%) 03/18/22 Piper Sandler Piper 'pounding the table' on 'mis-valued' Qualcomm 02/04/22 Baird Qualcomm price target raised to $250 from $200 at Baird 02/03/22 Bernstein Qualcomm price target raised to $250 from $225 at Bernstein 02/03/22 Cowen Qualcomm price target raised to $220 from $210 at Cowen FB Meta Platforms $224.95 / -2.82 (-1.24%) 03/28/22 Morgan Stanley Pinterest cut to Equal Weight at Morgan Stanley amid challenging user trends 03/25/22 UBS Meta Platforms newsfeed changes and Reelz to drive higher monetization, says UBS 03/17/22 Barclays Barclays says Meta opening up feed positive for DoubleVerify, Integral Ad 03/15/22 Cleveland Research Snap Q1 estimates raised at Cleveland Research F Ford $17.13 / -0.15 (-0.87%) 03/28/22 Citi Ford price target lowered to $18 from $23 at Citi 03/23/22 RBC Capital RBC cut 2022, 2023 auto forecast on lingering supply chain issues 03/21/22 Morgan Stanley Morgan Stanley sees Ford's FY26 BEV volume 1.5M units below company view 03/15/22 Jefferies Ford price target lowered to $18 from $20 at Jefferies TSLA Tesla $1,097.57 / +3.66 (+0.33%) 03/31/22 Morgan Stanley Tesla emerging as energy on-shore infrastructure company, says Morgan Stanley 03/30/22 Morgan Stanley Market saying Tesla 'far ahead' on securing EV supplies, says Morgan Stanley 03/30/22 Bernstein Innovation can allow Tesla to take price but only for so long, says Bernstein 03/29/22 Credit Suisse Credit Suisse expects Tesla Q1 deliveries of 307,000 MASI Masimo $148.79 / -6.28 (-4.05%) 03/31/22 Stifel Masimo price target lowered to $175 from $250 at Stifel 03/31/22 Piper Sandler Masimo shares likely to take 'another leg lower,' says Piper Sandler 03/17/22 Piper Sandler Masimo price target lowered to $160 from $200 at Piper Sandler 02/18/22 Needham Needham upgraded Masimo to Buy, sees selloff on Sound United deal as overdone VRRM Verra Mobility $16.57 / +0.89 (+5.68%) 03/29/22 Deutsche Bank Verra Mobility initiated with a Hold at Deutsche Bank 12/09/21 William Blair Verra Mobility selloff on secondary a buying opportunity, says William Blair 05/26/21 Morgan Stanley Verra Mobility downgraded to Equal Weight on valuation at Morgan Stanley 05/26/21 Morgan Stanley Verra Mobility downgraded to Equal Weight from Overweight at Morgan Stanley NNOX Nano-X Imaging $10.98 / +1.55 (+16.44%) 04/19/21 Ladenburg Ladenburg starts Nano-X Imaging at Buy with $52 price target 04/19/21 Ladenburg Nano-X Imaging initiated with a Buy at Ladenburg DARE Dare Bioscience $1.55 / +0.09 (+6.16%) 03/31/22 Roth Capital Dare Bioscience women's health pipeline remains valuable, says Roth Capital 01/19/22 Brookline Dare Bioscience assumed with a Buy at Brookline 07/12/21 Roth Capital Roth adds more 'SMID-cap' names to second half top picks 07/12/21 Roth Capital Dare Bioscience NIH agreement should offset costs, says Roth Capital BOLT Bolt Biotherapeutics $2.72 / -0.06 (-2.16%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel WBA VRRM VIPS TSLA TPX SNOW SHCR QCOM PATH NNOX NNDM MASI JPM IQ HPQ FLEX FIVE FB F EXFY DELL DARE COIN BOLT BIDU AMZN AMD AAPL WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) 03/31/22 Walgreens Boots Alliance backs FY22 EPS up low-single digits, consensus $5.02 03/31/22 Walgreens Boots Alliance reports Q2 adjusted EPS $1.59, consensus $1.40 03/30/22 Notable companies reporting before tomorrow's open VRRM Verra Mobility $16.57 / +0.89 (+5.68%) 03/31/22 Verra Mobility sees 2022 revenue $694M-$715M, consensus $645.38M 02/28/22 Verra Mobility sees FY21 revenue high end of $525M-$540M, consensus $538.95M 11/04/21 Verra Mobility reports Q3 adjusted EPS 27c, consensus 21c VIPS Vipshop $9.26 / +0.05 (+0.54%) 02/23/22 Vipshop sees Q1 revenue down 5% to flat, one estimate $4.83B 02/23/22 Vipshop reports Q4 EPS 41c, consensus 33c 12/27/21 Vipshop cuts Q4 revenue view to RMB 34.0B-35.8B, down 5% to flat y/y 11/18/21 Vipshop sees Q4 revenue RMB 35.8B-RMB 37.6B TSLA Tesla $1,097.57 / +3.66 (+0.33%) 01/26/22 Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26 01/26/22 Notable companies reporting after market close 10/20/21 Tesla reports Q3 non-GAAP EPS $1.86, consensus $1.58 10/20/21 Notable companies reporting after market close TPX Tempur Sealy $28.05 / -0.95 (-3.28%) 03/31/22 Tempur Sealy sees Q1 revenue up 15%, consensus $1.26B 02/22/22 Tempur Sealy sees FY22 EPS $3.65-$3.85, consensus $3.76 02/22/22 Tempur Sealy reports Q4 adjusted EPS 88c, consensus 96c 10/28/21 Tempur Sealy raises FY21 adjusted EPS view to $3.20-$3.30 from $3.10-$3.25 SNOW Snowflake $235.25 / +3.6 (+1.55%) 03/02/22 Snowflake sees FY23 product revenue $1.88B-$1.9B 03/02/22 Snowflake reports Q4 EPS (43c), consensus 3c 03/02/22 Notable companies reporting after market close 12/01/21 Snowflake reports Q3 EPS (51c), consensus (6c) SHCR Sharecare $2.73 / -0.55 (-16.79%) 03/31/22 Sharecare sees FY22 revenue $470M-$500M, consensus $539.63M 03/31/22 Sharecare sees Q1 revenue $95M-$98M, consensus $122.44M 03/31/22 Sharecare reports Q4 adjusted EPS 1c, consensus (3c) 11/10/21 Sharecare still sees FY21 revenue $414M-$415M, consensus $413.13M QCOM Qualcomm $154.02 / +1.295 (+0.85%) 02/02/22 Qualcomm sees Q2 adjusted EPS $2.80-$3.00, consensus $2.49 02/02/22 Qualcomm sees Q2 adjusted EPS $2.80-$3.00, consensus $2.49 02/02/22 Qualcomm reports Q1 adjusted EPS $3.23, consensus $3.01 02/02/22 Notable companies reporting after market close PATH UiPath $21.66 / -7.38 (-25.41%) 03/30/22 UiPath sees FY23 revenue $1.075B-$1.085B, consensus $1.16B 03/30/22 UiPath sees Q1 revenue $223M-$225M, consensus $243.1M 03/30/22 UiPath reports Q4 EPS 5c, consensus 3c 03/30/22 Notable companies reporting after market close NNOX Nano-X Imaging $10.98 / +1.55 (+16.44%) 03/31/22 Nano-X Imaging reports Q4 EPS (30c), consensus (33c) 11/17/21 Nano-X Imaging reports Q3 EPS (18c), consensus (28c) NNDM Nano Dimension $3.57 / -0.26 (-6.80%) 03/31/22 Nano Dimension reports Q4 EPS (62c) vs (20c) last year 01/31/22 Nano Dimension reports preliminary Q4 revenue $7M, up 255% over 4Q20 11/24/21 Nano Dimension reports Q3 EPS (7c) vs (46c) last year MASI Masimo $148.79 / -6.28 (-4.05%) 03/30/22 Masimo backs FY22 revenue view $1.35B, consensus $1.49B 02/15/22 Masimo sees FY22 adjusted EPS $4.34, consensus $4.33 02/15/22 Masimo reports Q4 adjusted EPS $1.21, consensus $1.10 01/11/22 Masimo sees FY22 EPS $4.34, consensus $4.35 JPM JPMorgan $138.58 / -1.91 (-1.36%) 01/14/22 JPMorgan reports Q4 EPS $3.33, consensus $3.01 01/13/22 Notable companies reporting before tomorrow's open 10/13/21 JPMorgan reports Q3 adjusted EPS $3.03, consensus $3.00 IQ iQIYI $4.64 / -0.405 (-8.03%) 03/01/22 iQIYI reports Q4 EPS (20c), consensus (32c) 11/17/21 iQIYI reports Q3 EPS (34c), consensus (35c) HPQ HP Inc. $36.74 / -2.095 (-5.39%) 03/28/22 Signs point to Turtle Beach as next takeover target, Citron says 02/28/22 HP Inc. raises FY22 EPS view to $4.18-$4.38 from $4.07-$4.27, consensus $4.39 02/28/22 HP Inc. sees Q2 EPS $1.02-$1.08, consensus $1.02 02/28/22 HP Inc. reports Q1 EPS $1.10, consensus $1.02 FLEX Flex $18.96 / +1.595 (+9.19%) 03/30/22 Flex still sees FY22 adjusted EPS $1.85-$1.90, consensus $1.72 03/30/22 Flex still sees Q4 adjusted EPS 41c-46c, consensus 40c 01/26/22 Flex sees FY22 adjusted EPS $1.85-$1.90, consensus $1.58 01/26/22 Flex sees Q4 adjusted EPS 41c-46c, consensus 39c FIVE Five Below $162.17 / +1.65 (+1.03%) 03/30/22 Five Below sees FY22 EPS $5.19-$5.70, consensus $5.86 03/30/22 Five Below sees Q1 EPS 54c-62c, consensus 89c 03/30/22 Five Below reports Q4 EPS $2.49, consensus $2.48 03/29/22 Notable companies reporting before tomorrow's open FB Meta Platforms $224.95 / -2.82 (-1.24%) 02/02/22 Meta sees Q1 revenue $27B-29B, consensus $30.14B 02/02/22 Meta reports Q4 EPS $3.67, consensus $3.84 10/25/21 Facebook reports Q3 EPS $3.22, consensus $3.19 F Ford $17.13 / -0.15 (-0.87%) 02/03/22 Ford reports Q4 adjusted EPS 26c, consensus 45c 10/27/21 Ford raises FY21 adjusted EBIT view to $10.5B-$11.5B from $9B-$10B 10/27/21 Ford reports Q3 adjusted EPS 51c, consensus 27c EXFY Expensify $16.27 / -2.365 (-12.69%) 03/30/22 Expensify sees Q1 revenue $38.6M-$39.6M, consensus $40.34M 03/30/22 Expensify reports Q4 EPS (82c) 12/16/21 Expensify sees Q4 revenue $38.2M-$39.2M, consensus $38.54M 12/16/21 Expensify reports Q3 EPS (18c), may not compare to consensus 42c DELL Dell Technologies $51.42 / -2.86 (-5.27%) 02/24/22 Dell Technologies reports Q4 adjusted EPS $1.72, consensus $1.95 02/24/22 Notable companies reporting after market close 11/23/21 Dell Technologies reports Q3 adjusted EPS $2.37, consensus $2.18 11/23/21 Notable companies reporting after market close DARE Dare Bioscience $1.55 / +0.09 (+6.16%) 03/31/22 Dare Bioscience reports 2021 EPS (63c), consensus (65c) 11/10/21 Dare Bioscience reports Q3 EPS (18c), consensus (13c) COIN Coinbase $193.50 / -3.2 (-1.63%) 02/24/22 Coinbase reports Q4 adjusted EBITDA $1.21B vs. $288M y/y 11/09/21 Coinbase reports Q3 EPS $1.62, consensus $1.56 11/09/21 Notable companies reporting after market close BOLT Bolt Biotherapeutics $2.72 / -0.06 (-2.16%) 03/30/22 Bolt Biotherapeutics reports Q4 EPS (73c), consensus (82c) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) BIDU Baidu $134.85 / -9.02 (-6.27%) 03/01/22 Baidu reports Q4 EPS $1.82, consensus $1.38 11/17/21 Baidu sees Q4 revenue $4.81B-$5.27B, consensus $5.1B 11/17/21 Baidu reports Q3 EPS $2.28, consensus $2.00 11/16/21 Notable companies reporting before tomorrow's open AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) 02/03/22 Amazon sees Q1 revenue $112B-$117B, consensus $120.11B 02/03/22 Amazon reports Q4 EPS $27.75 with gains vs. $14.09 a year ago 02/03/22 Notable companies reporting after market close 11/10/21 Affirm sees fiscal 2022 revenue $1.225B-$1.25B, consensus $1.20B AMD AMD $111.17 / -8.03 (-6.74%) 02/01/22 AMD sees FY22 revenue $21.5B, consensus $19.27B 02/01/22 AMD sees Q1 revenue $5B +/- $100M, consensus $4.32B 02/01/22 AMD reports Q4 EPS 92c, consensus 76c 02/01/22 Notable companies reporting after market close AAPL Apple $177.06 / -0.615 (-0.35%) 02/27/22 Berkshire operating earnings surge, Buffett repurchases record $27B in stock 01/27/22 Apple reports Q1 EPS $2.10, consensus $1.89 01/27/22 Notable companies reporting after market close 10/28/21 Apple reports Q4 EPS $1.24, consensus $1.24 07 Jan 08 Dec 10 Nov 19 Aug 29 Jun 18 Jun 14 Apr 14 Apr 21 Apr 06 Apr WBA VIPS TSLA SNOW QCOM NNOX JPM HPQ FB F DELL COIN BIDU AMZN AMLX AMD AAPL WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) 03/02/22 CVS, Walgreens, Walmart participating in test-to-treat program, MarketWatch says 01/30/22 Walgreens said to kick off Boots sale as Sycamore joins fray, Bloomberg says 01/14/22 Walgreens, CVS to shut down some pharmacies on weekends, WSJ reports 12/23/21 Amazon caps number of at-home Covid tests shoppers can purchase, CNBC says VIPS Vipshop $9.26 / +0.05 (+0.54%) 03/16/22 Chinese stocks jump as Beijing vows to keep markets stable, Reuters reports TSLA Tesla $1,097.57 / +3.66 (+0.33%) 03/31/22 Tesla extends production suspension at Shanghai factory, Reuters says 03/30/22 Tesla signs undisclosed nickel supply pact with Vale, Bloomberg reports 03/29/22 UAW President says no talks with Tesla on potential union vote, Reuters reports 03/29/22 Tesla supplier halts some Shanghai production amid Covid issues, Reuters says SNOW Snowflake $235.25 / +3.6 (+1.55%) 03/05/22 Cloud stocks have become a haven in tech, Barron's says QCOM Qualcomm $154.02 / +1.295 (+0.85%) 03/31/22 Qualcomm failed to land Meta as flagship AI chip customer, The Information says 01/04/22 Qualcomm and Microsoft team on new chips for AR glasses, The Verge reports 12/22/21 Amazon, other technology firms drop CES plans due to omicron, Reuters reports 12/20/21 Apple looking to develop own RF solutions, modem chips, DigiTimes reports NNOX Nano-X Imaging $10.98 / +1.55 (+16.44%) 12/02/21 Doctor tells Jerusalem Post Nano-X could be 'game-changer' in COVID-pneumonia JPM JPMorgan $138.58 / -1.91 (-1.36%) 03/25/22 SoftBank to seek valuation of at least $60B for Arm IPO, Bloomberg reports 03/23/22 JPMorgan CEO faces investor criticism over technology spending plan, FT reports 03/19/22 Chevron, Verizon among dividend stocks to choose for retirement, Barron's says HPQ HP Inc. $36.74 / -2.095 (-5.39%) 03/30/22 TSMC says demand for consumer electronics starting to slow, Nikkei Asia reports 01/28/22 HP wins fraud case in U.K. over Autonomy acquisition, CNBC says 01/01/22 Amazon looks particularly attractive after wild year for tech, Barron's says 10/29/21 HP forms task force to strengthen supply chain resilience, DigiTimes reports FB Meta Platforms $224.95 / -2.82 (-1.24%) 03/30/22 Apple at work on effort to bring more finance services in-house, Bloomberg says 03/30/22 Facebook paid GOP firm to orchestrate campaign against TikTok, WaPo reports F Ford $17.13 / -0.15 (-0.87%) 03/31/22 Ford plant down next week due to chip shortage, Automotive News' Martinez says 03/02/22 Ford sells Spin scooter unit to European shared mobility company, Verge says 03/01/22 Ford planning reorganization around EV, ICE as separate businesses, Reuters says 02/25/22 Ford idling Kansas City F-150 line next week amid chip shortage, Bloomberg says DELL Dell Technologies $51.42 / -2.86 (-5.27%) 10/24/21 HP stock looks like 'a screaming buy,' Barron's says 10/16/21 Spinoff could unlock value in Dell stock, Barron's says COIN Coinbase $193.50 / -3.2 (-1.63%) 03/16/22 Democrats split on whether to regulate crypto, Politico reports 03/09/22 Biden to order government to come up with plan to regulate crypto, NYT reports 01/20/22 NYC Mayor Adams' first paycheck to come in crypto via Coinbase, Reuters says 11/24/21 U.S Senate makes inquiries to stablecoin exchanges and issuers, Blockworks says BIDU Baidu $134.85 / -9.02 (-6.27%) 12/27/21 Investors likely to cheer China's new requirements on offshore IPOs, SCMP says 11/23/21 NetEase's Cloud Village launches scaled back Hong Kong IPO, WSJ reports 11/18/21 Baidu's Apollo Go plans to operate in 100 cities by 2030, TechCrunch says AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) 03/31/22 Amazon union election in Alabama sees 39% voter turnout, CNBC reports 03/31/22 Amazon hired influential pollster to fight unionization effort, CNBC reports 03/31/22 Amazon decides to renew Prime credit card tie-up with JPMorgan, CNBC reports 03/30/22 Hulu loses Paramount, MGM films as EPIX deal ends, The Streamable says AMLX Amylyx $13.40 / -1.55 (-10.37%) 01/13/22 Biogen working with Goldman to explore possible acquisitions, STAT says AMD AMD $111.17 / -8.03 (-6.74%) 02/13/22 Best-performing chip stock Synaptics still a buy, Barron's says 02/01/22 China to launch platform for collaboration with Intel, AMD, Nikkei reports 01/20/22 Xilinx-AMD deal on course for approval from China's SAMR, Dealreporter says 12/28/21 AMD will not have physical presence at CES 2022, Tom's Hardware says AAPL Apple $177.06 / -0.615 (-0.35%) 03/31/22 Apple reduces orders to China-based suppliers, DigiTimes reports 03/31/22 Some Hollywood partners frustrated with Apple TV+ operations, BI reports 03/31/22 Apple seeks to diversify memory chip suppliers, Bloomberg reports 03/30/22 Apple, Meta gave customer information to hackers, Bloomberg says WBA VRRM VIPS TPX SNOW QCOM PATH NNDM MASI JPM IQ HPQ FLEX FIVE FB F EXFY DELL DARE COIN BOLT AMZN AMLX AMD WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) 03/31/22 Fly Intel: Pre-market Movers 01/14/22 Wall Street in Fives - Must Read Lists at Midday 01/11/22 Wall Street in Fives - Must Read Lists for Tuesday 01/06/22 Wall Street in Fives - Must Read Lists for Thursday VRRM Verra Mobility $16.57 / +0.89 (+5.68%) 02/28/22 What You Missed On Wall Street On Monday 12/07/21 Fly Intel: After-Hours Movers VIPS Vipshop $9.26 / +0.05 (+0.54%) 03/16/22 What You Missed On Wall Street On Wednesday 03/16/22 What You Missed On Wall Street This Morning 02/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations TPX Tempur Sealy $28.05 / -0.95 (-3.28%) 11/08/21 Peloton downgrade, Discovery upgrade among today's top calls on Wall Street SNOW Snowflake $235.25 / +3.6 (+1.55%) 03/03/22 What You Missed On Wall Street On Thursday 03/03/22 What You Missed On Wall Street This Morning 03/03/22 Fly Intel: Pre-market Movers QCOM Qualcomm $154.02 / +1.295 (+0.85%) 03/22/22 What You Missed This Week in Video Games 02/03/22 Fly Intel: Pre-market Movers PATH UiPath $21.66 / -7.38 (-25.41%) 03/30/22 Fly Intel: After-Hours Movers 01/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/08/21 Fly Intel: After-Hours Movers NNDM Nano Dimension $3.57 / -0.26 (-6.80%) 01/31/22 Wall Street in Fives - Must Read Lists at Midday 11/24/21 Wall Street in Fives - Must Read Lists for Wednesday 11/24/21 Wall Street in Fives - Must Read Lists at Midday MASI Masimo $148.79 / -6.28 (-4.05%) 02/18/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/16/22 What You Missed On Wall Street On Wednesday 02/16/22 What You Missed On Wall Street This Morning JPM JPMorgan $138.58 / -1.91 (-1.36%) 03/23/22 What You Missed On Wall Street This Morning 02/28/22 What You Missed On Wall Street This Morning 02/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 01/14/22 Wall Street in Fives - Must Read Lists for Friday IQ iQIYI $4.64 / -0.405 (-8.03%) 03/01/22 What You Missed On Wall Street On Tuesday HPQ HP Inc. $36.74 / -2.095 (-5.39%) 03/28/22 Fly Intel: Pre-market Movers FLEX Flex $18.96 / +1.595 (+9.19%) 02/03/22 Wall Street in Fives - Must Read Lists for Thursday 02/03/22 Wall Street in Fives - Must Read Lists at Midday 02/02/22 Fly Intel: After-Hours Movers FIVE Five Below $162.17 / +1.65 (+1.03%) 03/30/22 What You Missed On Wall Street On Wednesday 03/30/22 What You Missed On Wall Street This Morning 03/30/22 Fly Intel: Pre-market Movers FB Meta Platforms $224.95 / -2.82 (-1.24%) 03/30/22 What You Missed This Week in Video Games F Ford $17.13 / -0.15 (-0.87%) 03/28/22 What You Missed This Week in EVs and Clean Energy 03/21/22 What You Missed This Week in EVs and Clean Energy 03/19/22 Opening Day: Cannabis name Akanda opens way above IPO pricing, pulls back EXFY Expensify $16.27 / -2.365 (-12.69%) 11/13/21 Opening Day: Electric truck maker Rivian soars in mega IPO DELL Dell Technologies $51.42 / -2.86 (-5.27%) 03/08/22 What You Missed On Wall Street On Tuesday 03/08/22 What You Missed On Wall Street This Morning 03/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations DARE Dare Bioscience $1.55 / +0.09 (+6.16%) 10/14/21 Fly Intel: Pre-market Movers COIN Coinbase $193.50 / -3.2 (-1.63%) 03/28/22 Crypto Currents: Late Day Look at Top Currencies and News 03/25/22 Bet On It: Sports betting stocks remain under pressure despite NCAA tournament 03/25/22 Here's What You Missed in Crypto This Week 03/21/22 What You Missed On Wall Street On Monday BOLT Bolt Biotherapeutics $2.72 / -0.06 (-2.16%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) 03/30/22 #SocialStocks: NAAG urges Snapchat and TikTok to add parental controls 03/29/22 What You Missed On Wall Street On Tuesday 03/29/22 What You Missed On Wall Street This Morning 03/25/22 What You Missed On Wall Street On Friday AMLX Amylyx $13.40 / -1.55 (-10.37%) 03/26/22 Opening Day: AN2 Therapeutics rises in public debut after upsized IPO 01/29/22 Opening Day: Credo rises in first trading day despite tough IPO market 01/13/22 Wall Street in Fives - Must Read Lists for Thursday AMD AMD $111.17 / -8.03 (-6.74%) 03/31/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/28/22 What You Missed On Wall Street On Monday 03/28/22 What You Missed On Wall Street This Morning 04/03/22 AAN 2002 Annual Meeting 03/31/22 Sharecare - SHCR 03/31/22 Nano-X Imaging - NNOX 03/31/22 Walgreens Boots Alliance - WBA 03/31/22 Nano Dimension - NNDM 03/31/22 Dare Bioscience - DARE 04/13/22 JPMorgan - JPM 04/27/22 Qualcomm - QCOM 04/28/22 Tempur Sealy - TPX 04/28/22 Apple - AAPL 05/03/22 Masimo - MASI 05/26/22 Dell Technologies - DELL 06/29/22 PDUFA Date for AMX0035 04/19/22 HP Inc. 05/05/22 Tempur Sealy International, Inc. 05/25/22 Amazon.com, Inc. WBA VIPS TSLA TPX SNOW QCOM PATH NNOX NNDM JPM IQ HPQ FLEX FIVE FB F EXFY DELL COIN BIDU AMZN AMLX AMD AAPL WBA Walgreens Boots Alliance $45.10 / -2.34 (-4.93%) 03/31/22 Unusually active option classes on open March 31st 03/24/22 Walgreen Boots call volume above normal and directionally bullish 03/04/22 Walgreen Boots call volume above normal and directionally bullish 01/06/22 Unusually active option classes on open January 6th VIPS Vipshop $9.26 / +0.05 (+0.54%) 01/21/22 Vipshop put volume heavy and directionally bearish 01/10/22 Vipshop call volume above normal and directionally bullish 12/23/21 Unusually active option classes on open December 23rd 12/03/21 Vipshop put volume heavy and directionally bearish TSLA Tesla $1,097.57 / +3.66 (+0.33%) 03/28/22 Early notable gainers among liquid option names on March 28th 03/24/22 Notable open interest changes for March 24th TPX Tempur Sealy $28.05 / -0.95 (-3.28%) 03/23/22 Tempur Sealy put volume heavy and directionally bearish 02/28/22 Tempur Sealy call volume above normal and directionally bullish SNOW Snowflake $235.25 / +3.6 (+1.55%) 03/28/22 Snowflake call volume above normal and directionally bullish 03/24/22 Snowflake put volume heavy and directionally bearish 03/04/22 Unusually active option classes on open March 4th 02/25/22 Unusually active option classes on open February 25th QCOM Qualcomm $154.02 / +1.295 (+0.85%) 02/02/22 Qualcomm options imply 8.1% move in share price post-earnings 02/02/22 Unusually active option classes on open February 2nd 01/05/22 Qualcomm call volume above normal and directionally bullish 12/09/21 Qualcomm call volume above normal and directionally bullish PATH UiPath $21.66 / -7.38 (-25.41%) 03/30/22 UiPath options imply 10.3% move in share price post-earnings 03/14/22 UiPath put buyer realizes 19% same-day gains 01/20/22 UiPath call volume above normal and directionally bullish 01/05/22 UiPath put volume heavy and directionally bearish NNOX Nano-X Imaging $10.98 / +1.55 (+16.44%) 03/17/22 Largest borrow rate increases among liquid names 12/16/21 Largest borrow rate increases among liquid names 11/30/21 Largest borrow rate increases among liquid names 11/29/21 Largest borrow rate increases among liquid names NNDM Nano Dimension $3.57 / -0.26 (-6.80%) 11/03/21 Unusually active option classes on open November 3rd 10/26/21 Nano Dimension call volume above normal and directionally bullish JPM JPMorgan $138.58 / -1.91 (-1.36%) 02/08/22 Early notable gainers among liquid option names on February 8th 01/14/22 Unusually active option classes on open January 14th 01/04/22 Unusually active option classes on open January 4th 11/24/21 Unusually active option classes on open November 24th IQ iQIYI $4.64 / -0.405 (-8.03%) 03/21/22 Largest borrow rate increases among liquid names 03/16/22 Unusually active option classes on open March 16th 03/01/22 Unusually active option classes on open March 1st HPQ HP Inc. $36.74 / -2.095 (-5.39%) 03/28/22 HP Inc. put volume heavy and directionally bearish 03/23/22 HP Inc. put volume heavy and directionally bearish 03/21/22 Unusually active option classes on open March 21st 02/28/22 HP Inc. put volume heavy and directionally bearish FLEX Flex $18.96 / +1.595 (+9.19%) 02/24/22 Flex put volume heavy and directionally bearish FIVE Five Below $162.17 / +1.65 (+1.03%) 12/01/21 Five Below options imply 8.4% move in share price post-earnings FB Meta Platforms $224.95 / -2.82 (-1.24%) 03/25/22 Early notable gainers among liquid option names on March 25th 03/24/22 Facebook call volume above normal and directionally bullish 03/17/22 Notable open interest changes for March 17th 03/16/22 Notable open interest changes for March 16th F Ford $17.13 / -0.15 (-0.87%) 03/23/22 Notable open interest changes for March 23rd 03/22/22 Early notable gainers among liquid option names on March 22nd EXFY Expensify $16.27 / -2.365 (-12.69%) 03/31/22 Six new option listings and one option delisting on March 31st DELL Dell Technologies $51.42 / -2.86 (-5.27%) 11/23/21 Dell Technologies options imply 4.8% move in share price post-earnings 11/22/21 Unusually active option classes on open November 22nd 11/03/21 Notable open interest changes for November 3rd 11/03/21 Thirteen new option listings on November 3rd COIN Coinbase $193.50 / -3.2 (-1.63%) 02/28/22 Coinbase call volume above normal and directionally bullish 12/28/21 Unusually active option classes on open December 28th 12/27/21 Coinbase call volume above normal and directionally bullish 12/15/21 Unusual call flow in option market yesterday BIDU Baidu $134.85 / -9.02 (-6.27%) 03/31/22 Baidu put volume heavy and directionally bearish 03/11/22 Baidu put volume heavy and directionally bearish AMZN Amazon.com $3,304.86 / -18.19 (-0.55%) 03/10/22 Early notable gainers among liquid option names on March 10th 02/04/22 Early notable gainers among liquid option names on February 4th 10/18/21 Alibaba plans to launch own cloud server chip, Caixin Global reports AMLX Amylyx $13.40 / -1.55 (-10.37%) 03/29/22 Three new option listings and one option delisting on March 29th AMD AMD $111.17 / -8.03 (-6.74%) 03/31/22 AMD options see early action as shares dip on downgrade 03/24/22 Advanced Micro call volume above normal and directionally bullish 03/22/22 Notable open interest changes for March 22nd 03/22/22 Advanced Micro call buyer realizes 12% same-day gains AAPL Apple $177.06 / -0.615 (-0.35%) 03/31/22 Notable open interest changes for March 31st 03/30/22 Notable open interest changes for March 30th 03/30/22 Apple call buyer realizes 25% same-day gains 03/29/22 Notable open interest changes for March 29th
Syndicate	Bolt Biotherapeutics files $250M mixed securities shelf 06:30 03/31/22 03/31 06:30 03/31/22 06:30 BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) ShowHide Related Items >><< Company News Street Research Earnings On The Fly BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 03/30/22 Bolt Biotherapeutics reports Q4 EPS (73c), consensus (82c) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce
Earnings	Bolt Biotherapeutics reports Q4 EPS (73c), consensus (82c) » 16:16 03/30/22 03/30 16:16 03/30/22 16:16 BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) Reports Q4 revenue… Reports Q4 revenue $508,000, consensus $370,000. Cash, cash equivalents, and marketable securities were $271.6M as of December 31, 2021, compared to $22.8M as of December 31, 2020. Bolt Biotherapeutics expects its cash balance to fund operations into 2024. "In 2021, we demonstrated for the first time that our HER2-targeting Boltbody ISAC can increase myeloid cell infiltration and repolarize macrophages in the tumor microenvironment, and thereby, established proof of mechanism for our pioneering Boltbody ISAC platform. In our Phase 1/2 study, BDC-1001 was well tolerated at all dose levels tested with no dose-limiting toxicities. At the lower dose levels evaluated to date, we have seen stable disease in multiple different tumor types and a partial response that has now persisted for more than 60 weeks," said Randall Schatzman, CEO of Bolt Biotherapeutics. "We continue to explore dose levels expected to achieve our targeted higher drug exposures, and look forward to determining the recommended Phase 2 dose for BDC-1001 as monotherapy and in combination with Opdivo." ShowHide Related Items >><< Company News Street Research Earnings On The Fly BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) BOLT Bolt Biotherapeutics $2.79 / -0.08 (-2.79%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce

Hot Stocks

Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer » 07:09

03/14/22

03/14

07:09

03/14/22

07:09

ELEV

Elevation Oncology

$2.99 / +0.01 (+0.34%)

, BOLT

Bolt Biotherapeutics

$2.84 / -0.235 (-7.64%)

Elevation Oncology (ELEV)…

Elevation Oncology (ELEV) announced the appointment of David Dornan, Ph.D. as the company's Chief Scientific Officer. Dr. Dornan joins Elevation Oncology from Bolt Biotherapeutics (BOLT).

ShowHide Related Items >><<

Company News
Street Research
Earnings
Syndicate
On The Fly
Events

ELEV
BOLT

ELEV Elevation Oncology

$2.99 / +0.01 (+0.34%)

BOLT Bolt Biotherapeutics

$2.84 / -0.235 (-7.64%)

ELEV
BOLT

ELEV Elevation Oncology

$2.99 / +0.01 (+0.34%)

03/04/22 Wedbush: Elevation Oncology price target lowered to $21 from $27 at Wedbush

12/23/21: Fly Intel: Top five analyst initiations

12/23/21 H.C. Wainwright: Elevation Oncology initiated with a Buy at H.C. Wainwright

07/20/21: Fly Intel: Top five analyst initiations

BOLT Bolt Biotherapeutics

$2.84 / -0.235 (-7.64%)

01/06/22 Morgan Stanley: Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

12/06/21 Stifel: Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel

ELEV
BOLT

ELEV Elevation Oncology

$2.99 / +0.01 (+0.34%)

BOLT Bolt Biotherapeutics

$2.84 / -0.235 (-7.64%)

25

Jun

BOLT

BOLT Bolt Biotherapeutics

$2.84 / -0.235 (-7.64%)

Over a quarter ago
Conference/Events	Guggenheim to hold a virtual conference » 04:55 02/11/22 02/11 04:55 02/11/22 04:55 ACET Adicet Bio $15.58 / +0.525 (+3.49%) , ADCT ADC Therapeutics $16.22 / -1.1 (-6.35%) , ALLO Allogene Therapeutics $10.63 / -0.415 (-3.76%) , BOLT Bolt Biotherapeutics $3.18 / -0.21 (-6.19%) , DCPH Deciphera $9.26 / -0.145 (-1.54%) , TNGX Tango Therapeutics $9.29 / +0.02 (+0.22%) , RLAY Relay Therapeutics $20.84 / -1.355 (-6.11%) , IMRX Immuneering $9.75 / -0.65 (-6.25%) , PMVP PMV Pharmaceuticals $16.26 / -0.13 (-0.79%) , FATE Fate Therapeutics $38.09 / -2.8 (-6.85%) , LLY Eli Lilly $239.61 / -3.625 (-1.49%) , ZYME Zymeworks $7.65 / -0.43 (-5.33%) , TARA Protara Therapeutics $5.38 / +0.25 (+4.87%) , ONTX Onconova $1.71 / -0.07 (-3.93%) , XLO Xilio Therapeutics $13.14 / +2.28 (+20.99%) , MGNX MacroGenics $11.49 / -0.27 (-2.30%) , KYMR Kymera Therapeutics $42.68 / -0.34 (-0.79%) , SWTX SpringsWorks Therapeutics $57.58 / -0.62 (-1.07%) , VBLT VBL Therapeutics $1.48 / +0.1 (+7.25%) , MRUS Merus $26.29 / +0.25 (+0.96%) , SRRA Sierra Oncology $31.95 / -2.35 (-6.85%) , IGMS IGM Biosciences $17.75 / -1.105 (-5.86%) , RPTX Repare Therapeutics $15.08 / -0.47 (-3.02%) , ERAS Erasca $11.98 / -0.39 (-3.15%) , BLUE Bluebird Bio $6.93 / -0.42 (-5.71%) , RVMD Revolution Medicines $21.16 / -1.37 (-6.08%) , RAIN Rain Therapeutics $7.49 / -0.13 (-1.71%) Virtual Oncology… Virtual Oncology Conference to be held on February 9-11. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZYME XLO VBLT TNGX TARA SWTX SRRA RPTX RLAY RAIN PMVP ONTX MRUS MGNX LLY KYMR IMRX IGMS FATE ERAS DCPH BOLT BLUE ALLO ADCT ACET ZYME Zymeworks $7.65 / -0.43 (-5.33%) 01/27/22 Zymeworks falls -11.8% 01/20/22 Zymeworks falls -6.2% 01/19/22 Zymeworks outlines strategic priorities for 2022 and 2023; reduces workforce 01/12/22 Zymeworks Chief Medical Officer buys 5K shares of common stock XLO Xilio Therapeutics $13.14 / +2.28 (+20.99%) 01/20/22 Xilio Therapeutics initiates patient dosing in Phase 1/2 trial of XTX202 12/02/21 Xilio Therapeutics expects cash, cash equivalents to fund into 2024 12/02/21 Xilio Therapeutics announces anticipated milestones for 2022 11/12/21 Xilio Therapeutics announces preclinical data on XTX301 at SITC meeting VBLT VBL Therapeutics $1.48 / +0.1 (+7.25%) 01/18/22 VBL Therapeutics appoints Matthew Trudeau as CCO 12/20/21 VBL Therapeutics selected for EUR17.5M of funding from EIC Accelerator 11/15/21 VBL Therapeutics expects cash to fund operations into 4Q23 10/05/21 VBL Therapeutics appoints Sam Backenroth as CFO TNGX Tango Therapeutics $9.29 / +0.02 (+0.22%) 01/24/22 Tango Therapeutics announces clearance of TNG908 IND, pipeline progress 11/09/21 Tango Therapeutics expects cash to fund operations into 2H24 11/01/21 Tango Therapeutics appoints Marc Rudoltz as CMO, Doug Barry as general counsel 09/30/21 Tango Therapeutics to present preclinical data on at AACR-NCI-EORTC 2021 TARA Protara Therapeutics $5.38 / +0.25 (+4.87%) 01/10/22 Protara Therapeutics appoints Jathin Bandaria as CMO 10/12/21 Protara Therapeutics announces FDA clearance of IND for TARA-002 09/13/21 Protara announces results from study on cholestasis in patients on PN SWTX SpringsWorks Therapeutics $57.58 / -0.62 (-1.07%) 12/10/21 SpringsWorks Therapeutics announces trial collaboration with AbbVie 12/06/21 SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study 11/29/21 SpringsWorks Therapeutics announces full enrollment of Phase 2b ReNeu trial 10/27/21 SpringsWorks Therapeutics begins expanded Phase 2 for nirogacestat in myeloma SRRA Sierra Oncology $31.95 / -2.35 (-6.85%) 01/25/22 Sierra Oncology trading resumes 01/25/22 Sierra provides update to support future commercialization of momelotinib 01/25/22 Sierra Oncology trading halted, news pending 01/25/22 Sierra provides update to support future commercialization of momelotinib RPTX Repare Therapeutics $15.08 / -0.47 (-3.02%) 12/21/21 Repare Therapeutics doses 1st patient in RP-6306 combo trial with gemcitabine 10/08/21 Repare Therapeutics presents preliminary data from Phase 1/2 TRESR trial 10/07/21 Repare Therapeutics issues statement on inadvertent issuance of RP-3500 abstract 09/07/21 Repare Therapeutics appoints Thomas Civik as chairman RLAY Relay Therapeutics $20.84 / -1.355 (-6.11%) 01/27/22 Relay Therapeutics treatment of cholangiocarcinoma granted orphan designation 01/04/22 Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion 12/10/21 Relay Therapeutics announces preclinical data on RLY-2608 10/08/21 Relay Therapeutics trading resumes RAIN Rain Therapeutics $7.49 / -0.13 (-1.71%) 01/05/22 Rain Therapeutics, Roche to collaborate on trial of milademetan combination 12/14/21 Rain Therapeutics added to Nasdaq Biotechnology Index 11/19/21 Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan PMVP PMV Pharmaceuticals $16.26 / -0.13 (-0.79%) 09/09/21 PMV Pharmaceuticals appoints Tim Smith as SVP, head of corporate development ONTX Onconova $1.71 / -0.07 (-3.93%) 12/02/21 Onconova presents preliminary data on rigosertib in RDEB-associated SCC 09/22/21 Onconova announces preliminary data from Phase 1/2a trial of oral rigosertib MRUS Merus $26.29 / +0.25 (+0.96%) 01/25/22 Merus names Shannon Campbell as Chief Commercial Officer 12/10/21 Merus presents updated analyst on zenocutuzumab combination study 12/02/21 Merus announces poster presentation on MCLA-145 at ESMO-IO 10/07/21 Merus presents early clinical data on MCLA-158, preclinical data on Zeno MGNX MacroGenics $11.49 / -0.27 (-2.30%) 01/10/22 Sesen Bio appoints Minori Rosales as chief development officer 12/27/21 I-Mab announces IND approval from China NMPA for Phase 2 trial of enoblituzumab 10/05/21 Zai Lab announces study of margetuximab in China met primary endpoint 09/28/21 I-Mab announces approval of phase 2 trial for enoblituzumab in China LLY Eli Lilly $239.61 / -3.625 (-1.49%) 02/10/22 Eli Lilly to supply 600K doses of AbCellera's Bebtelovimab to target omicron 02/10/22 Eli Lilly to supply up to 600,000 doses of bebtelovimab to U.S. government 02/10/22 Eli Lilly 'disappointed' with outcome of ODAC meeting on sintilimab 02/08/22 Rain Therapeutics announces key appointments to leadership team KYMR Kymera Therapeutics $42.68 / -0.34 (-0.79%) 01/18/22 Kymera Therapeutics appoints John Maraganore to board of directors 01/10/22 Kymera Therapeutics announces 2022 goals, milestones 12/16/21 Kymera Therapeutics discloses new KT-474 clinical data 12/13/21 Kymera Therapeutics presents preclinical data on STAT3 degraders IMRX Immuneering $9.75 / -0.65 (-6.25%) 12/06/21 Immuneering Corporation (Class A Stock) trading resumes 12/06/21 Immuneering Corporation (Class A Stock) trading halted, volatility trading pause 09/20/21 Immuneering to be added to Russell 2000 Index IGMS IGM Biosciences $17.75 / -1.105 (-5.86%) 02/09/22 IGM Biosciences advances IGM-6268 into clinical trials to treat COVID-19 01/05/22 Icosavax appoints John Shiver to board of directors 12/12/21 IGM presents data from IGM-2323 in patients with Advanced B Cell Malignancies 12/08/21 IGM to collaborate on study of IgM, IgA antibodies to prevent malaria FATE Fate Therapeutics $38.09 / -2.8 (-6.85%) 01/10/22 Fate Therapeutics announces FDA clearance for FT536 12/14/21 Cathie Wood's ARK Investment bought 196K shares of Fate Therapeutics on Tuesday 12/13/21 Fate Therapeutics reports 'positive' interim Phase 1 data from FT596 program 12/13/21 Fate Therapeutics announces data from Phase 1 study of FT516 ERAS Erasca $11.98 / -0.39 (-3.15%) 01/18/22 Erasca appoints Tesvich-Bonora as CPO, promotes Shoemaker to SVP of Research 12/17/21 Erasca announces FDA clearance of IND application for ERAS-801 12/14/21 Erasca added to Nasdaq Biotechnology Index 09/22/21 Erasca announces first patient dosed in HERKULES-3 trial evaluating ERAS-007 DCPH Deciphera $9.26 / -0.145 (-1.54%) 01/24/22 Deciphera presents Phase 3 results of ripretinib in gastrointestinal tumor 01/11/22 Oryzon appoints Ana Limon as SVP, clinical development, global medical affairs 12/21/21 Deciphera says UK MHRA grants MA for Qinlock or ripretinib to treat GIST 11/30/21 Deciphera Pharmaceuticals trading resumes BOLT Bolt Biotherapeutics $3.18 / -0.21 (-6.19%) 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial 11/19/21 Bolt Biotherapeutics appoints Brian O'Callaghan, Frank Lee to board BLUE Bluebird Bio $6.93 / -0.42 (-5.71%) 01/18/22 Bluebird Bio falls after FDA extends review for biologics licensing applications 01/11/22 Bluebird Bio cash, cash and cash equivalents $442M at year-end 01/11/22 Bluebird Bio provides update on program milestones ALLO Allogene Therapeutics $10.63 / -0.415 (-3.76%) 01/14/22 Allogene Therapeutics director Belldegrun buys 155,039 common shares 01/11/22 Allogene Therapeutics announces collaboration license agreement with Antion 01/10/22 Allogene Therapeutics says FDA lifts hold on clinical trials 01/10/22 Allogene announces removal of FDA clinical hold across AlloCAR T trials ADCT ADC Therapeutics $16.22 / -1.1 (-6.35%) 01/18/22 ADC Therapeutics enters exclusive Zynlonta license agreement with MTPC 10/29/21 ADC Therapeutics announces validation of Zynlonta MAA by EMA 09/29/21 ADC Therapeutics joint venture doses first patient in Zynlonta study 09/27/21 ADC Therapeutics doses first patient in ADCT-901 trial ACET Adicet Bio $15.58 / +0.525 (+3.49%) 12/06/21 Adicet Bio trading resumes 12/06/21 Adicet Bio trading halted, volatility trading pause 12/06/21 Adicet Bio announces interim data from Phase 1 study of ADI-001 11/18/21 Adicet Bio appoints Michael Kauffman to board of directors ACET ADCT ALLO BOLT DCPH TNGX RLAY IMRX PMVP FATE LLY ZYME TARA ONTX XLO MGNX KYMR SWTX VBLT MRUS SRRA IGMS RPTX ERAS BLUE RVMD RAIN ACET Adicet Bio $15.58 / +0.525 (+3.49%) 01/03/22 Guggenheim ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim 12/06/21 BTIG Adicet Bio data highlights 'impressive' anti-tumor responses, says BTIG 12/06/21 Canaccord Canaccord remains bullish on Adicet after 'highly positive' interim ADI-001 data 12/06/21 Guggenheim Adicet Bio price target raised to $33 from $22 at Guggenheim ADCT ADC Therapeutics $16.22 / -1.1 (-6.35%) 02/01/22 Morgan Stanley ADC Therapeutics price target lowered to $29 from $47 at Morgan Stanley 11/08/21 Wolfe Research ADC Therapeutics initiated with an Outperform at Wolfe Research 09/07/21 Cantor Fitzgerald ADC Therapeutics selloff on CMO departure overdone, says Cantor Fitzgerald 08/09/21 RBC Capital ADC Therapeutics initiated with an Outperform at RBC Capital ALLO Allogene Therapeutics $10.63 / -0.415 (-3.76%) 01/10/22 Stifel Allogene ASH update may be weighing on shares despite holds lifted, says Stifel 01/06/22 Wells Fargo Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16 01/03/22 Guggenheim Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim 01/03/22 B. Riley iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022 BOLT Bolt Biotherapeutics $3.18 / -0.21 (-6.19%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 SVB Leerink Bolt Biotherapeutics initiated with an Outperform at SVB Leerink DCPH Deciphera $9.26 / -0.145 (-1.54%) 02/08/22 Piper Sandler Deciphera's Q4 update was in-line, says Piper Sandler 12/01/21 H.C. Wainwright Deciphera price target lowered to $15 from $25 at H.C. Wainwright 11/30/21 Piper Sandler Deciphera price target lowered to $11 from $14 at Piper Sandler 11/08/21 Barclays Deciphera downgraded to Equal Weight at Barclays after GIST trial miss TNGX Tango Therapeutics $9.29 / +0.02 (+0.22%) 09/20/21 SVB Leerink SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform 09/20/21 SVB Leerink Tango Therapeutics initiated with an Outperform at SVB Leerink 09/07/21 Fly Intel: Top five analyst initiations 09/07/21 Wedbush Tango Therapeutics initiated with an Outperform at Wedbush RLAY Relay Therapeutics $20.84 / -1.355 (-6.11%) 02/01/22 Berenberg Relay Therapeutics initiated with a Buy at Berenberg 01/03/22 Guggenheim Relay Therapeutics price target lowered to $45 from $52 at Guggenheim 11/08/21 Jefferies Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts 08/17/21 H.C. Wainwright Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright IMRX Immuneering $9.75 / -0.65 (-6.25%) 01/07/22 Piper Sandler Immuneering initiated with an Overweight at Piper Sandler 01/03/22 Guggenheim Immuneering price target lowered to $30 from $42 at Guggenheim 08/24/21 Morgan Stanley Immuneering initiated with an Equal Weight at Morgan Stanley 08/24/21 Jefferies Immuneering initiated with a Buy at Jefferies PMVP PMV Pharmaceuticals $16.26 / -0.13 (-0.79%) 09/22/21 Goldman Sachs PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs 08/19/21 Oppenheimer PMV Pharmaceuticals initiated with a Perform at Oppenheimer 08/02/21 Guggenheim PMV Pharmaceuticals initiated with a Buy at Guggenheim 07/29/21 H.C. Wainwright PMV Pharmaceuticals initiated with a Buy at H.C. Wainwright FATE Fate Therapeutics $38.09 / -2.8 (-6.85%) 02/10/22 BMO Capital Fate Therapeutics assumed with a Market Perform at BMO Capital 01/03/22 Guggenheim Fate Therapeutics price target lowered to $78 from $107 at Guggenheim 12/30/21 Mizuho Mizuho announces top oncology stock picks for 2022 12/15/21 Wedbush Wedbush upgrades Fate Therapeutics to Outperform, ups price target to $74 LLY Eli Lilly $239.61 / -3.625 (-1.49%) 02/04/22 Morgan Stanley Eli Lilly price target lowered to $265 from $272 at Morgan Stanley 02/04/22 Mizuho Eli Lilly changes to Alzheimer's strategy make sense, says Mizuho 02/03/22 Truist Eli Lilly thinks final Alzheimer's NCD 'may not change very much,' says Truist 01/21/22 DZ Bank Eli Lilly upgraded to Buy from Hold at DZ Bank ZYME Zymeworks $7.65 / -0.43 (-5.33%) 02/09/22 Wells Fargo Zymeworks price target lowered to $45 from $56 at Wells Fargo 12/10/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James 12/10/21 SVB Leerink Zymeworks upgraded to Outperform from Market Perform at SVB Leerink 12/09/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James TARA Protara Therapeutics $5.38 / +0.25 (+4.87%) 06/04/21 H.C. Wainwright Protara Therapeutics initiated with a Buy at H.C. Wainwright 04/26/21 Oppenheimer Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer ONTX Onconova $1.71 / -0.07 (-3.93%) 09/28/21 Guggenheim Onconova price target lowered to $12 from $29 at Guggenheim 05/18/21 Guggenheim Onconova initiated with a Buy at Guggenheim XLO Xilio Therapeutics $13.14 / +2.28 (+20.99%) 01/10/22 H.C. Wainwright Xilio Therapeutics initiated with a Buy at H.C. Wainwright 11/16/21 Morgan Stanley Xilio Therapeutics initiated with an Overweight at Morgan Stanley 11/16/21 Raymond James Xilio Therapeutics initiated with an Outperform at Raymond James 11/16/21 Guggenheim Xilio Therapeutics initiated with a Buy at Guggenheim MGNX MacroGenics $11.49 / -0.27 (-2.30%) 02/10/22 BMO Capital MacroGenics initiated with an Outperform at BMO Capital 02/03/22 SMBC Nikko MacroGenics initiated with an Outperform at SMBC Nikko 11/17/21 Guggenheim MacroGenics assumed with a Buy at Guggenheim 10/19/21 JMP Securities MacroGenics initiated with an Outperform at JMP Securities KYMR Kymera Therapeutics $42.68 / -0.34 (-0.79%) 02/10/22 Wells Fargo Wells Fargo bullish on Kymera Therapeutics, initiates with an Overweight 02/09/22 Wells Fargo Kymera Therapeutics initiated with an Overweight at Wells Fargo 01/03/22 Piper Sandler Piper names Kymera Therapeutics a top pick for 2022, ups target SWTX SpringsWorks Therapeutics $57.58 / -0.62 (-1.07%) 10/27/21 Wedbush Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data 09/08/21 JPMorgan SpringsWorks price target raised to $105 from $97 at JPMorgan 07/21/21 H.C. Wainwright SpringsWorks price target raised to $136 from $124 at H.C. Wainwright 07/20/21 Goldman Sachs SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs VBLT VBL Therapeutics $1.48 / +0.1 (+7.25%) 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines 06/03/21 Roth Capital Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update 05/18/21 Guggenheim VBL Therapeutics initiated with a Buy at Guggenheim MRUS Merus $26.29 / +0.25 (+0.96%) 02/10/22 BMO Capital Merus initiated with an Outperform at BMO Capital 02/10/22 Needham Merus initiated with a Buy at Needham 11/17/21 Fly Intel: Top five analyst initiations SRRA Sierra Oncology $31.95 / -2.35 (-6.85%) 01/31/22 H.C. Wainwright Sierra Oncology price target raised to $51 from $35 at H.C. Wainwright 01/27/22 Oppenheimer Sierra Oncology price target raised to $38 from $32 at Oppenheimer 11/30/21 Cantor Fitzgerald Sierra Oncology price target raised to $39 from $33 at Cantor Fitzgerald 11/05/21 H.C. Wainwright Sierra Oncology price target raised to $35 from $29 at H.C. Wainwright IGMS IGM Biosciences $17.75 / -1.105 (-5.86%) 01/03/22 Guggenheim IGM Biosciences price target lowered to $55 from $100 at Guggenheim 12/16/21 H.C. Wainwright IGM Biosciences price target lowered to $76 from $114 at H.C. Wainwright 12/14/21 Baird IGM Biosciences price target lowered to $65 from $90 at Baird 12/13/21 Morgan Stanley Morgan Stanley cuts IGM Biosciences as lack of dose response raises concerns RPTX Repare Therapeutics $15.08 / -0.47 (-3.02%) 11/18/21 Northland Repare Therapeutics price target raised to $45 from $40 at Northland 11/10/21 Stifel Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report 09/22/21 Stifel Repare Therapeutics initiated with a Buy at Stifel 09/13/21 H.C. Wainwright Repare Therapeutics initiated with a Buy at H.C. Wainwright ERAS Erasca $11.98 / -0.39 (-3.15%) 01/03/22 Guggenheim Erasca price target lowered to $20 from $25 at Guggenheim 08/10/21 Fly Intel: Top five analyst initiations 08/10/21 Evercore ISI Erasca initiated with an Outperform at Evercore ISI 08/10/21 JPMorgan Erasca initiated with an Overweight at JPMorgan BLUE Bluebird Bio $6.93 / -0.42 (-5.71%) 01/05/22 Wells Fargo Avrobio price target lowered to $8 from $36 at Wells Fargo 12/06/21 Cowen Cowen starts Crispr at Market Perform as applications 'need maturing' 11/12/21 BMO Capital Bluebird Bio price target lowered to $13 from $21 at BMO Capital 11/08/21 Canaccord 2seventy Bio initiated with a Buy at Canaccord RVMD Revolution Medicines $21.16 / -1.37 (-6.08%) 11/12/21 H.C. Wainwright Revolution Medicines price target raised to $38 from $31 at H.C. Wainwright 09/22/21 Stifel Revolution Medicines initiated with a Hold at Stifel 08/17/21 H.C. Wainwright Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright 08/12/21 Fly Intel: Top five analyst downgrades RAIN Rain Therapeutics $7.49 / -0.13 (-1.71%) 01/03/22 Guggenheim Rain Therapeutics price target lowered to $20 from $26 at Guggenheim 11/10/21 Piper Sandler Rain Therapeutics price target raised to $26 from $25 at Piper Sandler 09/14/21 Fly Intel: Top five analyst downgrades 09/14/21 Goldman Sachs Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs ZYME XLO VBLT TNGX TARA SWTX SRRA RVMD RPTX RLAY RAIN PMVP MRUS MGNX LLY KYMR IMRX IGMS FATE ERAS DCPH BOLT BLUE ALLO ADCT ACET ZYME Zymeworks $7.65 / -0.43 (-5.33%) 11/03/21 Zymeworks reports Q3 EPS ($1.25), consensus ($1.17) XLO Xilio Therapeutics $13.14 / +2.28 (+20.99%) 12/02/21 Xilio Therapeutics reports Q3 EPS ($21.27), four estimates ($1.60) VBLT VBL Therapeutics $1.48 / +0.1 (+7.25%) 11/15/21 VBL Therapeutics reports Q3 EPS (9c), consensus (11c) 08/16/21 VBL Therapeutics reports Q2 EPS (12c), consensus (11c) TNGX Tango Therapeutics $9.29 / +0.02 (+0.22%) 11/09/21 Tango Therapeutics reports Q3 EPS (28c), consensus (28c) TARA Protara Therapeutics $5.38 / +0.25 (+4.87%) 11/04/21 Protara Therapeutics reports Q3 EPS (96c), three estimates ($1.01) SWTX SpringsWorks Therapeutics $57.58 / -0.62 (-1.07%) 11/04/21 SpringsWorks Therapeutics reports Q3 EPS (84c), consensus (76c) SRRA Sierra Oncology $31.95 / -2.35 (-6.85%) 11/05/21 Sierra Oncology reports Q3 adjusted EPS ($1.86), consensus ($1.78) RVMD Revolution Medicines $21.16 / -1.37 (-6.08%) 11/10/21 Revolution Medicines sees FY21 GAAP net loss $170M-$190M 11/10/21 Revolution Medicines reports Q3 EPS (72c), consensus (62c) 08/11/21 Revolution Medicines reports Q2 EPS (60c), consensus (48c) RPTX Repare Therapeutics $15.08 / -0.47 (-3.02%) 11/10/21 Repare Therapeutics reports Q3 EPS (83c), consensus (71c) 11/10/21 Repare Therapeutics reports Q3 EPS (83c), consensus (71c) 08/12/21 Repare Therapeutics reports Q2 EPS (71c), consensus (60c) RLAY Relay Therapeutics $20.84 / -1.355 (-6.11%) 11/10/21 Relay Therapeutics reports Q3 EPS (66c), consensus (64c) 08/12/21 Relay Therapeutics reports Q2 EPS ($2.10), consensus (45c) RAIN Rain Therapeutics $7.49 / -0.13 (-1.71%) 11/10/21 Rain Therapeutics reports Q3 EPS (70c), consensus (48c) PMVP PMV Pharmaceuticals $16.26 / -0.13 (-0.79%) 11/12/21 PMV Pharmaceuticals reports Q3 EPS (33c), consensus (30c) 08/13/21 PMV Pharmaceuticals reports Q2 EPS (29c), consensus (27c) MRUS Merus $26.29 / +0.25 (+0.96%) 11/02/21 Merus reports Q3 EPS (39c), consensus (68c) MGNX MacroGenics $11.49 / -0.27 (-2.30%) 11/02/21 MacroGenics reports Q3 EPS (86c), consensus (69c) LLY Eli Lilly $239.61 / -3.625 (-1.49%) 02/03/22 Eli Lilly backs FY22 EPS view $8.50-$8.65, consensus $7.54 02/03/22 Eli Lilly reports Q4 EPS $2.49, consensus $2.18 02/02/22 Notable companies reporting before tomorrow's open KYMR Kymera Therapeutics $42.68 / -0.34 (-0.79%) 11/10/21 Kymera Therapeutics reports Q3 EPS (56c), consensus (42c) IMRX Immuneering $9.75 / -0.65 (-6.25%) 11/09/21 Immuneering reports Q3 EPS (47c), consensus (57c) IGMS IGM Biosciences $17.75 / -1.105 (-5.86%) 11/04/21 IGM Biosciences reports Q3 EPS ($1.32), consensus ($1.37) FATE Fate Therapeutics $38.09 / -2.8 (-6.85%) 11/04/21 Fate Therapeutics reports Q3 EPS (45c), consensus (58c) ERAS Erasca $11.98 / -0.39 (-3.15%) 11/10/21 Erasca reports Q3 EPS (46c), consensus (32c) DCPH Deciphera $9.26 / -0.145 (-1.54%) 02/08/22 Deciphera reports Q4 EPS ($1.51), consensus ($1.33) 11/02/21 Deciphera Pharmaceuticals reports Q3 EPS ($1.37), consensus ($1.28) BOLT Bolt Biotherapeutics $3.18 / -0.21 (-6.19%) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) 08/12/21 Bolt Biotherapeutics reports Q2 EPS (64c), consensus (43c) BLUE Bluebird Bio $6.93 / -0.42 (-5.71%) 11/05/21 Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60) 11/05/21 Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60) ALLO Allogene Therapeutics $10.63 / -0.415 (-3.76%) 11/04/21 Allogene Therapeutics reports Q3 EPS (57c), consensus (56c) ADCT ADC Therapeutics $16.22 / -1.1 (-6.35%) 11/02/21 ADC Therapeutics reports Q3 adjusted EPS (59c), consensus (92c) ACET Adicet Bio $15.58 / +0.525 (+3.49%) 11/10/21 Adicet Bio reports Q3 EPS (44c), consensus (44c) 08/12/21 Adicet Bio reports Q2 EPS (34c), consensus (53c) 27 Jan 27 Jan 08 Dec 05 Nov 28 Oct 22 Oct 13 Oct 24 Sep 30 Jul 16 Jul 01 Jul 23 Apr 09 Apr 02 Mar ZYME LLY ZYME Zymeworks $7.65 / -0.43 (-5.33%) 09/17/21 Zymeworks data 'could intensify potential sale talks,' Dealreporter says LLY Eli Lilly $239.61 / -3.625 (-1.49%) 02/10/22 FDA expresses concerns about quality of China-developed drugs, WSJ reports 01/25/22 White House limits use of Regeneron, Lilly Covid-19 antibody drugs, WSJ reports 12/22/21 Most monoclonal antibody treatments failing against omicron, NY Times reports 12/03/21 FDA planning fast review of omicron vaccines and drugs, WSJ reports ZYME XLO TARA SRRA RLAY ONTX MRUS MGNX LLY IMRX IGMS FATE DCPH BOLT BLUE ALLO ACET ZYME Zymeworks $7.65 / -0.43 (-5.33%) 09/17/21 Wall Street in Fives - Must Read Lists for Friday 09/17/21 Wall Street in Fives - Must Read Lists at Midday XLO Xilio Therapeutics $13.14 / +2.28 (+20.99%) 10/23/21 Opening Day: Portillo's jumps in debut as Vita Coco falls short of IPO goals TARA Protara Therapeutics $5.38 / +0.25 (+4.87%) 01/03/22 Fly Insider: Ashford, Coinbase among week's notable insider trades SRRA Sierra Oncology $31.95 / -2.35 (-6.85%) 02/07/22 Fly Insider: Kodiak, Accenture among week's notable insider trades RLAY Relay Therapeutics $20.84 / -1.355 (-6.11%) 10/12/21 Fly Intel: Pre-market Movers 10/11/21 Fly Intel: After-Hours Movers 08/12/21 Fly Intel: After-Hours Movers ONTX Onconova $1.71 / -0.07 (-3.93%) 09/23/21 Fly Intel: After-Hours Movers MRUS Merus $26.29 / +0.25 (+0.96%) 10/07/21 Wall Street in Fives - Must Read Lists for Thursday 10/07/21 Wall Street in Fives - Must Read Lists at Midday MGNX MacroGenics $11.49 / -0.27 (-2.30%) 09/16/21 Wall Street in Fives - Must Read Lists for Thursday 09/16/21 Wall Street in Fives - Must Read Lists at Midday 09/07/21 Fly Intel: After-Hours Movers LLY Eli Lilly $239.61 / -3.625 (-1.49%) 02/03/22 Wall Street in Fives - Must Read Lists for Thursday 02/03/22 Wall Street in Fives - Must Read Lists at Midday 01/28/22 Wall Street in Fives - Must Read Lists for Friday 01/13/22 Meet Prothena: Fly exclusive interview with CEO Gene Kinney IMRX Immuneering $9.75 / -0.65 (-6.25%) 08/21/21 Opening Day: Sportradar files for IPO after SPAC talks break off IGMS IGM Biosciences $17.75 / -1.105 (-5.86%) 12/13/21 Wall Street in Fives - Must Read Lists for Monday 12/13/21 Wall Street in Fives - Must Read Lists at Midday 12/13/21 Fly Intel: Pre-market Movers FATE Fate Therapeutics $38.09 / -2.8 (-6.85%) 08/20/21 Wall Street in Fives - Must Read Lists for Friday 08/20/21 Wall Street in Fives - Must Read Lists at Midday 08/19/21 Fly Intel: After-Hours Movers DCPH Deciphera $9.26 / -0.145 (-1.54%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday BOLT Bolt Biotherapeutics $3.18 / -0.21 (-6.19%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce BLUE Bluebird Bio $6.93 / -0.42 (-5.71%) 01/18/22 Fly Intel: Wall Street's top stories for Tuesday 01/11/22 Fly Intel: Pre-market Movers 12/20/21 Wall Street in Fives - Must Read Lists for Monday 12/20/21 Wall Street in Fives - Must Read Lists at Midday ALLO Allogene Therapeutics $10.63 / -0.415 (-3.76%) 01/10/22 Wall Street in Fives - Must Read Lists for Monday 01/10/22 Wall Street in Fives - Must Read Lists at Midday 10/08/21 Wall Street in Fives - Must Read Lists for Friday 10/08/21 Wall Street in Fives - Must Read Lists at Midday ACET Adicet Bio $15.58 / +0.525 (+3.49%) 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 02/18/22 ASCO Genitourinary Cancers Symposium 2022 03/08/22 42nd Annual Healthcare Conference 06/03/22 2022 ASCO Annual Meeting 02/24/22 Zymeworks - ZYME 04/28/22 Eli Lilly - LLY 08/19/22 PDUFA Date for betibeglogene autotemcel (beti-cel) 02/14/22 Eli Lilly 02/15/22 Eli Lilly SRRA LLY BLUE ALLO SRRA Sierra Oncology $31.95 / -2.35 (-6.85%) 02/02/22 Ten new option listings and three option delistings on February 2nd LLY Eli Lilly $239.61 / -3.625 (-1.49%) 12/15/21 Early notable gainers among liquid option names on December 15th 11/19/21 Early notable gainers among liquid option names on November 19th 11/17/21 Early notable gainers among liquid option names on November 17th BLUE Bluebird Bio $6.93 / -0.42 (-5.71%) 11/08/21 Two new option listings and two option delistings on November 8th 11/05/21 One new option listing and one option delisting on November 5th ALLO Allogene Therapeutics $10.63 / -0.415 (-3.76%) 10/14/21 Unusually active option classes on open October 14th
Conference/Events	Guggenheim to hold a virtual conference » 04:55 02/10/22 02/10 04:55 02/10/22 04:55 ACET Adicet Bio $15.05 / +1.39 (+10.18%) , ADCT ADC Therapeutics $17.37 / +1.07 (+6.56%) , ALLO Allogene Therapeutics $11.05 / +0.245 (+2.27%) , BOLT Bolt Biotherapeutics $3.39 / +0.08 (+2.42%) , DCPH Deciphera $9.43 / +1.29 (+15.85%) , TNGX Tango Therapeutics $9.20 / +0.205 (+2.28%) , RLAY Relay Therapeutics $22.19 / +1.33 (+6.38%) , IMRX Immuneering $10.40 / +0.38 (+3.79%) , PMVP PMV Pharmaceuticals $16.44 / +1.24 (+8.16%) , FATE Fate Therapeutics $40.93 / +1.29 (+3.25%) , LLY Eli Lilly $243.24 / +3.355 (+1.40%) , ZYME Zymeworks $8.07 / +0.45 (+5.91%) , TARA Protara Therapeutics $5.13 / +0.12 (+2.40%) , ONTX Onconova $1.78 / -0.01 (-0.56%) , XLO Xilio Therapeutics $10.87 / +0.54 (+5.23%) , MGNX MacroGenics $11.76 / +0.25 (+2.17%) , KYMR Kymera Therapeutics $43.02 / +1.46 (+3.51%) , SWTX SpringsWorks Therapeutics $58.20 / +5.09 (+9.58%) , VBLT VBL Therapeutics $1.38 / +0.09 (+6.98%) , MRUS Merus $26.02 / +0.78 (+3.09%) , SRRA Sierra Oncology $34.21 / +1.98 (+6.14%) , IGMS IGM Biosciences $18.86 / +1.625 (+9.43%) , RPTX Repare Therapeutics $15.55 / +0.6 (+4.01%) , ERAS Erasca $12.39 / +0.52 (+4.38%) , BLUE Bluebird Bio $7.35 / +0.32 (+4.55%) , RVMD Revolution Medicines $22.57 / +1.17 (+5.47%) , RAIN Rain Therapeutics $7.62 / +0.41 (+5.69%) Virtual Oncology… Virtual Oncology Conference to be held on February 9-11. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZYME XLO VBLT TNGX TARA SWTX SRRA RPTX RLAY RAIN PMVP ONTX MRUS MGNX LLY KYMR IMRX IGMS FATE ERAS DCPH BOLT BLUE ALLO ADCT ACET ZYME Zymeworks $8.07 / +0.45 (+5.91%) 01/27/22 Zymeworks falls -11.8% 01/20/22 Zymeworks falls -6.2% 01/19/22 Zymeworks outlines strategic priorities for 2022 and 2023; reduces workforce 01/12/22 Zymeworks Chief Medical Officer buys 5K shares of common stock XLO Xilio Therapeutics $10.87 / +0.54 (+5.23%) 01/20/22 Xilio Therapeutics initiates patient dosing in Phase 1/2 trial of XTX202 12/02/21 Xilio Therapeutics expects cash, cash equivalents to fund into 2024 12/02/21 Xilio Therapeutics announces anticipated milestones for 2022 11/12/21 Xilio Therapeutics announces preclinical data on XTX301 at SITC meeting VBLT VBL Therapeutics $1.38 / +0.09 (+6.98%) 01/18/22 VBL Therapeutics appoints Matthew Trudeau as CCO 12/20/21 VBL Therapeutics selected for EUR17.5M of funding from EIC Accelerator 11/15/21 VBL Therapeutics expects cash to fund operations into 4Q23 10/05/21 VBL Therapeutics appoints Sam Backenroth as CFO TNGX Tango Therapeutics $9.20 / +0.205 (+2.28%) 01/24/22 Tango Therapeutics announces clearance of TNG908 IND, pipeline progress 11/09/21 Tango Therapeutics expects cash to fund operations into 2H24 11/01/21 Tango Therapeutics appoints Marc Rudoltz as CMO, Doug Barry as general counsel 09/30/21 Tango Therapeutics to present preclinical data on at AACR-NCI-EORTC 2021 TARA Protara Therapeutics $5.13 / +0.12 (+2.40%) 01/10/22 Protara Therapeutics appoints Jathin Bandaria as CMO 10/12/21 Protara Therapeutics announces FDA clearance of IND for TARA-002 09/13/21 Protara announces results from study on cholestasis in patients on PN SWTX SpringsWorks Therapeutics $58.20 / +5.09 (+9.58%) 12/10/21 SpringsWorks Therapeutics announces trial collaboration with AbbVie 12/06/21 SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study 11/29/21 SpringsWorks Therapeutics announces full enrollment of Phase 2b ReNeu trial 10/27/21 SpringsWorks Therapeutics begins expanded Phase 2 for nirogacestat in myeloma SRRA Sierra Oncology $34.21 / +1.98 (+6.14%) 01/25/22 Sierra Oncology trading resumes 01/25/22 Sierra provides update to support future commercialization of momelotinib 01/25/22 Sierra Oncology trading halted, news pending 01/25/22 Sierra provides update to support future commercialization of momelotinib RPTX Repare Therapeutics $15.55 / +0.6 (+4.01%) 12/21/21 Repare Therapeutics doses 1st patient in RP-6306 combo trial with gemcitabine 10/08/21 Repare Therapeutics presents preliminary data from Phase 1/2 TRESR trial 10/07/21 Repare Therapeutics issues statement on inadvertent issuance of RP-3500 abstract 09/07/21 Repare Therapeutics appoints Thomas Civik as chairman RLAY Relay Therapeutics $22.19 / +1.33 (+6.38%) 01/27/22 Relay Therapeutics treatment of cholangiocarcinoma granted orphan designation 01/04/22 Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion 12/10/21 Relay Therapeutics announces preclinical data on RLY-2608 10/08/21 Relay Therapeutics trading resumes RAIN Rain Therapeutics $7.62 / +0.41 (+5.69%) 01/05/22 Rain Therapeutics, Roche to collaborate on trial of milademetan combination 12/14/21 Rain Therapeutics added to Nasdaq Biotechnology Index 11/19/21 Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan PMVP PMV Pharmaceuticals $16.44 / +1.24 (+8.16%) 09/09/21 PMV Pharmaceuticals appoints Tim Smith as SVP, head of corporate development ONTX Onconova $1.78 / -0.01 (-0.56%) 12/02/21 Onconova presents preliminary data on rigosertib in RDEB-associated SCC 09/22/21 Onconova announces preliminary data from Phase 1/2a trial of oral rigosertib MRUS Merus $26.02 / +0.78 (+3.09%) 01/25/22 Merus names Shannon Campbell as Chief Commercial Officer 12/10/21 Merus presents updated analyst on zenocutuzumab combination study 12/02/21 Merus announces poster presentation on MCLA-145 at ESMO-IO 10/07/21 Merus presents early clinical data on MCLA-158, preclinical data on Zeno MGNX MacroGenics $11.76 / +0.25 (+2.17%) 01/10/22 Sesen Bio appoints Minori Rosales as chief development officer 12/27/21 I-Mab announces IND approval from China NMPA for Phase 2 trial of enoblituzumab 10/05/21 Zai Lab announces study of margetuximab in China met primary endpoint 09/28/21 I-Mab announces approval of phase 2 trial for enoblituzumab in China LLY Eli Lilly $243.24 / +3.355 (+1.40%) 02/08/22 Rain Therapeutics announces key appointments to leadership team 02/01/22 Veru enters into clinical trial collaboration, supply agreement with Eli Lilly 01/28/22 Eli Lilly reports $1B investment in new manufacturing facility in North Carolina 01/28/22 Eli Lilly reports $1B investment in new manufacturing facility in North Carolina KYMR Kymera Therapeutics $43.02 / +1.46 (+3.51%) 01/18/22 Kymera Therapeutics appoints John Maraganore to board of directors 01/10/22 Kymera Therapeutics announces 2022 goals, milestones 12/16/21 Kymera Therapeutics discloses new KT-474 clinical data 12/13/21 Kymera Therapeutics presents preclinical data on STAT3 degraders IMRX Immuneering $10.40 / +0.38 (+3.79%) 12/06/21 Immuneering Corporation (Class A Stock) trading resumes 12/06/21 Immuneering Corporation (Class A Stock) trading halted, volatility trading pause 09/20/21 Immuneering to be added to Russell 2000 Index IGMS IGM Biosciences $18.86 / +1.625 (+9.43%) 02/09/22 IGM Biosciences advances IGM-6268 into clinical trials to treat COVID-19 01/05/22 Icosavax appoints John Shiver to board of directors 12/12/21 IGM presents data from IGM-2323 in patients with Advanced B Cell Malignancies 12/08/21 IGM to collaborate on study of IgM, IgA antibodies to prevent malaria FATE Fate Therapeutics $40.93 / +1.29 (+3.25%) 01/10/22 Fate Therapeutics announces FDA clearance for FT536 12/14/21 Cathie Wood's ARK Investment bought 196K shares of Fate Therapeutics on Tuesday 12/13/21 Fate Therapeutics reports 'positive' interim Phase 1 data from FT596 program 12/13/21 Fate Therapeutics announces data from Phase 1 study of FT516 ERAS Erasca $12.39 / +0.52 (+4.38%) 01/18/22 Erasca appoints Tesvich-Bonora as CPO, promotes Shoemaker to SVP of Research 12/17/21 Erasca announces FDA clearance of IND application for ERAS-801 12/14/21 Erasca added to Nasdaq Biotechnology Index 09/22/21 Erasca announces first patient dosed in HERKULES-3 trial evaluating ERAS-007 DCPH Deciphera $9.43 / +1.29 (+15.85%) 01/24/22 Deciphera presents Phase 3 results of ripretinib in gastrointestinal tumor 01/11/22 Oryzon appoints Ana Limon as SVP, clinical development, global medical affairs 12/21/21 Deciphera says UK MHRA grants MA for Qinlock or ripretinib to treat GIST 11/30/21 Deciphera Pharmaceuticals trading resumes BOLT Bolt Biotherapeutics $3.39 / +0.08 (+2.42%) 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial 11/19/21 Bolt Biotherapeutics appoints Brian O'Callaghan, Frank Lee to board BLUE Bluebird Bio $7.35 / +0.32 (+4.55%) 01/18/22 Bluebird Bio falls after FDA extends review for biologics licensing applications 01/11/22 Bluebird Bio cash, cash and cash equivalents $442M at year-end 01/11/22 Bluebird Bio provides update on program milestones ALLO Allogene Therapeutics $11.05 / +0.245 (+2.27%) 01/14/22 Allogene Therapeutics director Belldegrun buys 155,039 common shares 01/11/22 Allogene Therapeutics announces collaboration license agreement with Antion 01/10/22 Allogene Therapeutics says FDA lifts hold on clinical trials 01/10/22 Allogene announces removal of FDA clinical hold across AlloCAR T trials ADCT ADC Therapeutics $17.37 / +1.07 (+6.56%) 01/18/22 ADC Therapeutics enters exclusive Zynlonta license agreement with MTPC 10/29/21 ADC Therapeutics announces validation of Zynlonta MAA by EMA 09/29/21 ADC Therapeutics joint venture doses first patient in Zynlonta study 09/27/21 ADC Therapeutics doses first patient in ADCT-901 trial ACET Adicet Bio $15.05 / +1.39 (+10.18%) 12/06/21 Adicet Bio trading resumes 12/06/21 Adicet Bio trading halted, volatility trading pause 12/06/21 Adicet Bio announces interim data from Phase 1 study of ADI-001 11/18/21 Adicet Bio appoints Michael Kauffman to board of directors ACET ADCT ALLO BOLT DCPH TNGX RLAY IMRX PMVP FATE LLY ZYME TARA ONTX XLO MGNX KYMR SWTX VBLT MRUS SRRA IGMS RPTX ERAS BLUE RVMD RAIN ACET Adicet Bio $15.05 / +1.39 (+10.18%) 01/03/22 Guggenheim ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim 12/06/21 BTIG Adicet Bio data highlights 'impressive' anti-tumor responses, says BTIG 12/06/21 Canaccord Canaccord remains bullish on Adicet after 'highly positive' interim ADI-001 data 12/06/21 Guggenheim Adicet Bio price target raised to $33 from $22 at Guggenheim ADCT ADC Therapeutics $17.37 / +1.07 (+6.56%) 02/01/22 Morgan Stanley ADC Therapeutics price target lowered to $29 from $47 at Morgan Stanley 11/08/21 Wolfe Research ADC Therapeutics initiated with an Outperform at Wolfe Research 09/07/21 Cantor Fitzgerald ADC Therapeutics selloff on CMO departure overdone, says Cantor Fitzgerald 08/09/21 RBC Capital ADC Therapeutics initiated with an Outperform at RBC Capital ALLO Allogene Therapeutics $11.05 / +0.245 (+2.27%) 01/10/22 Stifel Allogene ASH update may be weighing on shares despite holds lifted, says Stifel 01/06/22 Wells Fargo Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16 01/03/22 Guggenheim Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim 01/03/22 B. Riley iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022 BOLT Bolt Biotherapeutics $3.39 / +0.08 (+2.42%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 SVB Leerink Bolt Biotherapeutics initiated with an Outperform at SVB Leerink DCPH Deciphera $9.43 / +1.29 (+15.85%) 02/08/22 Piper Sandler Deciphera's Q4 update was in-line, says Piper Sandler 12/01/21 H.C. Wainwright Deciphera price target lowered to $15 from $25 at H.C. Wainwright 11/30/21 Piper Sandler Deciphera price target lowered to $11 from $14 at Piper Sandler 11/08/21 Barclays Deciphera downgraded to Equal Weight at Barclays after GIST trial miss TNGX Tango Therapeutics $9.20 / +0.205 (+2.28%) 09/20/21 SVB Leerink SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform 09/20/21 SVB Leerink Tango Therapeutics initiated with an Outperform at SVB Leerink 09/07/21 Fly Intel: Top five analyst initiations 09/07/21 Wedbush Tango Therapeutics initiated with an Outperform at Wedbush RLAY Relay Therapeutics $22.19 / +1.33 (+6.38%) 02/01/22 Berenberg Relay Therapeutics initiated with a Buy at Berenberg 01/03/22 Guggenheim Relay Therapeutics price target lowered to $45 from $52 at Guggenheim 11/08/21 Jefferies Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts 08/17/21 H.C. Wainwright Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright IMRX Immuneering $10.40 / +0.38 (+3.79%) 01/07/22 Piper Sandler Immuneering initiated with an Overweight at Piper Sandler 01/03/22 Guggenheim Immuneering price target lowered to $30 from $42 at Guggenheim 08/24/21 Morgan Stanley Immuneering initiated with an Equal Weight at Morgan Stanley 08/24/21 Jefferies Immuneering initiated with a Buy at Jefferies PMVP PMV Pharmaceuticals $16.44 / +1.24 (+8.16%) 09/22/21 Goldman Sachs PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs 08/19/21 Oppenheimer PMV Pharmaceuticals initiated with a Perform at Oppenheimer 08/02/21 Guggenheim PMV Pharmaceuticals initiated with a Buy at Guggenheim 07/29/21 H.C. Wainwright PMV Pharmaceuticals initiated with a Buy at H.C. Wainwright FATE Fate Therapeutics $40.93 / +1.29 (+3.25%) 01/03/22 Guggenheim Fate Therapeutics price target lowered to $78 from $107 at Guggenheim 12/30/21 Mizuho Mizuho announces top oncology stock picks for 2022 12/15/21 Wedbush Wedbush upgrades Fate Therapeutics to Outperform, ups price target to $74 12/15/21 Wedbush Fate Therapeutics upgraded to Outperform from Neutral at Wedbush LLY Eli Lilly $243.24 / +3.355 (+1.40%) 02/04/22 Morgan Stanley Eli Lilly price target lowered to $265 from $272 at Morgan Stanley 02/04/22 Mizuho Eli Lilly changes to Alzheimer's strategy make sense, says Mizuho 02/03/22 Truist Eli Lilly thinks final Alzheimer's NCD 'may not change very much,' says Truist 01/21/22 DZ Bank Eli Lilly upgraded to Buy from Hold at DZ Bank ZYME Zymeworks $8.07 / +0.45 (+5.91%) 02/09/22 Wells Fargo Zymeworks price target lowered to $45 from $56 at Wells Fargo 12/10/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James 12/10/21 SVB Leerink Zymeworks upgraded to Outperform from Market Perform at SVB Leerink 12/09/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James TARA Protara Therapeutics $5.13 / +0.12 (+2.40%) 06/04/21 H.C. Wainwright Protara Therapeutics initiated with a Buy at H.C. Wainwright 04/26/21 Oppenheimer Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer ONTX Onconova $1.78 / -0.01 (-0.56%) 09/28/21 Guggenheim Onconova price target lowered to $12 from $29 at Guggenheim 05/18/21 Guggenheim Onconova initiated with a Buy at Guggenheim XLO Xilio Therapeutics $10.87 / +0.54 (+5.23%) 01/10/22 H.C. Wainwright Xilio Therapeutics initiated with a Buy at H.C. Wainwright 11/16/21 Morgan Stanley Xilio Therapeutics initiated with an Overweight at Morgan Stanley 11/16/21 Raymond James Xilio Therapeutics initiated with an Outperform at Raymond James 11/16/21 Guggenheim Xilio Therapeutics initiated with a Buy at Guggenheim MGNX MacroGenics $11.76 / +0.25 (+2.17%) 02/03/22 SMBC Nikko MacroGenics initiated with an Outperform at SMBC Nikko 11/17/21 Guggenheim MacroGenics assumed with a Buy at Guggenheim 10/19/21 JMP Securities MacroGenics initiated with an Outperform at JMP Securities 10/14/21 BTIG MacroGenics assumed with a Buy at BTIG KYMR Kymera Therapeutics $43.02 / +1.46 (+3.51%) 02/09/22 Wells Fargo Kymera Therapeutics initiated with an Overweight at Wells Fargo 01/03/22 Piper Sandler Piper names Kymera Therapeutics a top pick for 2022, ups target 10/13/21 Brookline Kymera Therapeutics initiated with Buy, $80 target at Brookline SWTX SpringsWorks Therapeutics $58.20 / +5.09 (+9.58%) 10/27/21 Wedbush Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data 09/08/21 JPMorgan SpringsWorks price target raised to $105 from $97 at JPMorgan 07/21/21 H.C. Wainwright SpringsWorks price target raised to $136 from $124 at H.C. Wainwright 07/20/21 Goldman Sachs SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs VBLT VBL Therapeutics $1.38 / +0.09 (+6.98%) 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines 06/03/21 Roth Capital Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update 05/18/21 Guggenheim VBL Therapeutics initiated with a Buy at Guggenheim MRUS Merus $26.02 / +0.78 (+3.09%) 11/17/21 Fly Intel: Top five analyst initiations 11/17/21 Guggenheim Merus assumed with a Buy at Guggenheim 11/12/21 H.C. Wainwright Merus price target raised to $45 from $30 at H.C. Wainwright SRRA Sierra Oncology $34.21 / +1.98 (+6.14%) 01/31/22 H.C. Wainwright Sierra Oncology price target raised to $51 from $35 at H.C. Wainwright 01/27/22 Oppenheimer Sierra Oncology price target raised to $38 from $32 at Oppenheimer 11/30/21 Cantor Fitzgerald Sierra Oncology price target raised to $39 from $33 at Cantor Fitzgerald 11/05/21 H.C. Wainwright Sierra Oncology price target raised to $35 from $29 at H.C. Wainwright IGMS IGM Biosciences $18.86 / +1.625 (+9.43%) 01/03/22 Guggenheim IGM Biosciences price target lowered to $55 from $100 at Guggenheim 12/16/21 H.C. Wainwright IGM Biosciences price target lowered to $76 from $114 at H.C. Wainwright 12/14/21 Baird IGM Biosciences price target lowered to $65 from $90 at Baird 12/13/21 Morgan Stanley Morgan Stanley cuts IGM Biosciences as lack of dose response raises concerns RPTX Repare Therapeutics $15.55 / +0.6 (+4.01%) 11/18/21 Northland Repare Therapeutics price target raised to $45 from $40 at Northland 11/10/21 Stifel Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report 09/22/21 Stifel Repare Therapeutics initiated with a Buy at Stifel 09/13/21 H.C. Wainwright Repare Therapeutics initiated with a Buy at H.C. Wainwright ERAS Erasca $12.39 / +0.52 (+4.38%) 01/03/22 Guggenheim Erasca price target lowered to $20 from $25 at Guggenheim 08/10/21 Fly Intel: Top five analyst initiations 08/10/21 Evercore ISI Erasca initiated with an Outperform at Evercore ISI 08/10/21 JPMorgan Erasca initiated with an Overweight at JPMorgan BLUE Bluebird Bio $7.35 / +0.32 (+4.55%) 01/05/22 Wells Fargo Avrobio price target lowered to $8 from $36 at Wells Fargo 12/06/21 Cowen Cowen starts Crispr at Market Perform as applications 'need maturing' 11/12/21 BMO Capital Bluebird Bio price target lowered to $13 from $21 at BMO Capital 11/08/21 Canaccord 2seventy Bio initiated with a Buy at Canaccord RVMD Revolution Medicines $22.57 / +1.17 (+5.47%) 11/12/21 H.C. Wainwright Revolution Medicines price target raised to $38 from $31 at H.C. Wainwright 09/22/21 Stifel Revolution Medicines initiated with a Hold at Stifel 08/17/21 H.C. Wainwright Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright 08/12/21 Fly Intel: Top five analyst downgrades RAIN Rain Therapeutics $7.62 / +0.41 (+5.69%) 01/03/22 Guggenheim Rain Therapeutics price target lowered to $20 from $26 at Guggenheim 11/10/21 Piper Sandler Rain Therapeutics price target raised to $26 from $25 at Piper Sandler 09/14/21 Fly Intel: Top five analyst downgrades 09/14/21 Goldman Sachs Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs ZYME XLO VBLT TNGX TARA SWTX SRRA RVMD RPTX RLAY RAIN PMVP MRUS MGNX LLY KYMR IMRX IGMS FATE ERAS DCPH BOLT BLUE ALLO ADCT ACET ZYME Zymeworks $8.07 / +0.45 (+5.91%) 11/03/21 Zymeworks reports Q3 EPS ($1.25), consensus ($1.17) XLO Xilio Therapeutics $10.87 / +0.54 (+5.23%) 12/02/21 Xilio Therapeutics reports Q3 EPS ($21.27), four estimates ($1.60) VBLT VBL Therapeutics $1.38 / +0.09 (+6.98%) 11/15/21 VBL Therapeutics reports Q3 EPS (9c), consensus (11c) 08/16/21 VBL Therapeutics reports Q2 EPS (12c), consensus (11c) TNGX Tango Therapeutics $9.20 / +0.205 (+2.28%) 11/09/21 Tango Therapeutics reports Q3 EPS (28c), consensus (28c) TARA Protara Therapeutics $5.13 / +0.12 (+2.40%) 11/04/21 Protara Therapeutics reports Q3 EPS (96c), three estimates ($1.01) SWTX SpringsWorks Therapeutics $58.20 / +5.09 (+9.58%) 11/04/21 SpringsWorks Therapeutics reports Q3 EPS (84c), consensus (76c) SRRA Sierra Oncology $34.21 / +1.98 (+6.14%) 11/05/21 Sierra Oncology reports Q3 adjusted EPS ($1.86), consensus ($1.78) RVMD Revolution Medicines $22.57 / +1.17 (+5.47%) 11/10/21 Revolution Medicines sees FY21 GAAP net loss $170M-$190M 11/10/21 Revolution Medicines reports Q3 EPS (72c), consensus (62c) 08/11/21 Revolution Medicines reports Q2 EPS (60c), consensus (48c) RPTX Repare Therapeutics $15.55 / +0.6 (+4.01%) 11/10/21 Repare Therapeutics reports Q3 EPS (83c), consensus (71c) 11/10/21 Repare Therapeutics reports Q3 EPS (83c), consensus (71c) 08/12/21 Repare Therapeutics reports Q2 EPS (71c), consensus (60c) RLAY Relay Therapeutics $22.19 / +1.33 (+6.38%) 11/10/21 Relay Therapeutics reports Q3 EPS (66c), consensus (64c) 08/12/21 Relay Therapeutics reports Q2 EPS ($2.10), consensus (45c) RAIN Rain Therapeutics $7.62 / +0.41 (+5.69%) 11/10/21 Rain Therapeutics reports Q3 EPS (70c), consensus (48c) 08/10/21 Rain Therapeutics reports Q2 EPS (39c), consensus (60c) PMVP PMV Pharmaceuticals $16.44 / +1.24 (+8.16%) 11/12/21 PMV Pharmaceuticals reports Q3 EPS (33c), consensus (30c) 08/13/21 PMV Pharmaceuticals reports Q2 EPS (29c), consensus (27c) MRUS Merus $26.02 / +0.78 (+3.09%) 11/02/21 Merus reports Q3 EPS (39c), consensus (68c) MGNX MacroGenics $11.76 / +0.25 (+2.17%) 11/02/21 MacroGenics reports Q3 EPS (86c), consensus (69c) LLY Eli Lilly $243.24 / +3.355 (+1.40%) 02/03/22 Eli Lilly backs FY22 EPS view $8.50-$8.65, consensus $7.54 02/03/22 Eli Lilly reports Q4 EPS $2.49, consensus $2.18 02/02/22 Notable companies reporting before tomorrow's open KYMR Kymera Therapeutics $43.02 / +1.46 (+3.51%) 11/10/21 Kymera Therapeutics reports Q3 EPS (56c), consensus (42c) IMRX Immuneering $10.40 / +0.38 (+3.79%) 11/09/21 Immuneering reports Q3 EPS (47c), consensus (57c) IGMS IGM Biosciences $18.86 / +1.625 (+9.43%) 11/04/21 IGM Biosciences reports Q3 EPS ($1.32), consensus ($1.37) FATE Fate Therapeutics $40.93 / +1.29 (+3.25%) 11/04/21 Fate Therapeutics reports Q3 EPS (45c), consensus (58c) ERAS Erasca $12.39 / +0.52 (+4.38%) 11/10/21 Erasca reports Q3 EPS (46c), consensus (32c) DCPH Deciphera $9.43 / +1.29 (+15.85%) 02/08/22 Deciphera reports Q4 EPS ($1.51), consensus ($1.33) 11/02/21 Deciphera Pharmaceuticals reports Q3 EPS ($1.37), consensus ($1.28) BOLT Bolt Biotherapeutics $3.39 / +0.08 (+2.42%) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) 08/12/21 Bolt Biotherapeutics reports Q2 EPS (64c), consensus (43c) BLUE Bluebird Bio $7.35 / +0.32 (+4.55%) 11/05/21 Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60) 11/05/21 Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60) ALLO Allogene Therapeutics $11.05 / +0.245 (+2.27%) 11/04/21 Allogene Therapeutics reports Q3 EPS (57c), consensus (56c) ADCT ADC Therapeutics $17.37 / +1.07 (+6.56%) 11/02/21 ADC Therapeutics reports Q3 adjusted EPS (59c), consensus (92c) ACET Adicet Bio $15.05 / +1.39 (+10.18%) 11/10/21 Adicet Bio reports Q3 EPS (44c), consensus (44c) 08/12/21 Adicet Bio reports Q2 EPS (34c), consensus (53c) 27 Jan 27 Jan 08 Dec 05 Nov 28 Oct 22 Oct 13 Oct 24 Sep 30 Jul 16 Jul 01 Jul 23 Apr 09 Apr 02 Mar 11 Feb ZYME LLY ZYME Zymeworks $8.07 / +0.45 (+5.91%) 09/17/21 Zymeworks data 'could intensify potential sale talks,' Dealreporter says LLY Eli Lilly $243.24 / +3.355 (+1.40%) 01/25/22 White House limits use of Regeneron, Lilly Covid-19 antibody drugs, WSJ reports 12/22/21 Most monoclonal antibody treatments failing against omicron, NY Times reports 12/03/21 FDA planning fast review of omicron vaccines and drugs, WSJ reports 11/30/21 COVID-19 antibody drugs struggle with omnicron, WSJ reports ZYME XLO TARA SRRA RLAY ONTX MRUS MGNX LLY IMRX IGMS FATE DCPH BOLT BLUE ALLO ACET ZYME Zymeworks $8.07 / +0.45 (+5.91%) 09/17/21 Wall Street in Fives - Must Read Lists for Friday 09/17/21 Wall Street in Fives - Must Read Lists at Midday XLO Xilio Therapeutics $10.87 / +0.54 (+5.23%) 10/23/21 Opening Day: Portillo's jumps in debut as Vita Coco falls short of IPO goals TARA Protara Therapeutics $5.13 / +0.12 (+2.40%) 01/03/22 Fly Insider: Ashford, Coinbase among week's notable insider trades SRRA Sierra Oncology $34.21 / +1.98 (+6.14%) 02/07/22 Fly Insider: Kodiak, Accenture among week's notable insider trades RLAY Relay Therapeutics $22.19 / +1.33 (+6.38%) 10/12/21 Fly Intel: Pre-market Movers 10/11/21 Fly Intel: After-Hours Movers 08/12/21 Fly Intel: After-Hours Movers ONTX Onconova $1.78 / -0.01 (-0.56%) 09/23/21 Fly Intel: After-Hours Movers MRUS Merus $26.02 / +0.78 (+3.09%) 10/07/21 Wall Street in Fives - Must Read Lists for Thursday 10/07/21 Wall Street in Fives - Must Read Lists at Midday MGNX MacroGenics $11.76 / +0.25 (+2.17%) 09/16/21 Wall Street in Fives - Must Read Lists for Thursday 09/16/21 Wall Street in Fives - Must Read Lists at Midday 09/07/21 Fly Intel: After-Hours Movers LLY Eli Lilly $243.24 / +3.355 (+1.40%) 02/03/22 Wall Street in Fives - Must Read Lists for Thursday 02/03/22 Wall Street in Fives - Must Read Lists at Midday 01/28/22 Wall Street in Fives - Must Read Lists for Friday 01/13/22 Meet Prothena: Fly exclusive interview with CEO Gene Kinney IMRX Immuneering $10.40 / +0.38 (+3.79%) 08/21/21 Opening Day: Sportradar files for IPO after SPAC talks break off IGMS IGM Biosciences $18.86 / +1.625 (+9.43%) 12/13/21 Wall Street in Fives - Must Read Lists for Monday 12/13/21 Wall Street in Fives - Must Read Lists at Midday 12/13/21 Fly Intel: Pre-market Movers FATE Fate Therapeutics $40.93 / +1.29 (+3.25%) 08/20/21 Wall Street in Fives - Must Read Lists for Friday 08/20/21 Wall Street in Fives - Must Read Lists at Midday 08/19/21 Fly Intel: After-Hours Movers DCPH Deciphera $9.43 / +1.29 (+15.85%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday BOLT Bolt Biotherapeutics $3.39 / +0.08 (+2.42%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce BLUE Bluebird Bio $7.35 / +0.32 (+4.55%) 01/18/22 Fly Intel: Wall Street's top stories for Tuesday 01/11/22 Fly Intel: Pre-market Movers 12/20/21 Wall Street in Fives - Must Read Lists for Monday 12/20/21 Wall Street in Fives - Must Read Lists at Midday ALLO Allogene Therapeutics $11.05 / +0.245 (+2.27%) 01/10/22 Wall Street in Fives - Must Read Lists for Monday 01/10/22 Wall Street in Fives - Must Read Lists at Midday 10/08/21 Wall Street in Fives - Must Read Lists for Friday 10/08/21 Wall Street in Fives - Must Read Lists at Midday ACET Adicet Bio $15.05 / +1.39 (+10.18%) 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 02/11/22 Virtual Oncology Conference 02/18/22 ASCO Genitourinary Cancers Symposium 2022 03/08/22 42nd Annual Healthcare Conference 06/03/22 2022 ASCO Annual Meeting 02/24/22 Zymeworks - ZYME 04/28/22 Eli Lilly - LLY 08/19/22 PDUFA Date for betibeglogene autotemcel (beti-cel) 02/14/22 Eli Lilly 02/15/22 Eli Lilly SRRA LLY BLUE ALLO SRRA Sierra Oncology $34.21 / +1.98 (+6.14%) 02/02/22 Ten new option listings and three option delistings on February 2nd LLY Eli Lilly $243.24 / +3.355 (+1.40%) 12/15/21 Early notable gainers among liquid option names on December 15th 11/19/21 Early notable gainers among liquid option names on November 19th 11/17/21 Early notable gainers among liquid option names on November 17th BLUE Bluebird Bio $7.35 / +0.32 (+4.55%) 11/08/21 Two new option listings and two option delistings on November 8th 11/05/21 One new option listing and one option delisting on November 5th ALLO Allogene Therapeutics $11.05 / +0.245 (+2.27%) 10/14/21 Unusually active option classes on open October 14th
Conference/Events	Guggenheim to hold a virtual conference » 10:21 02/09/22 02/09 10:21 02/09/22 10:21 ACET Adicet Bio $14.21 / +0.55 (+4.03%) , ADCT ADC Therapeutics $16.70 / +0.4 (+2.45%) , ALLO Allogene Therapeutics $11.12 / +0.32 (+2.96%) , BOLT Bolt Biotherapeutics $3.35 / +0.04 (+1.21%) , DCPH Deciphera $8.89 / +0.75 (+9.21%) , TNGX Tango Therapeutics $9.00 / + (+0.00%) , RLAY Relay Therapeutics $21.64 / +0.78 (+3.74%) , IMRX Immuneering $9.94 / -0.08 (-0.80%) , PMVP PMV Pharmaceuticals $15.61 / +0.41 (+2.70%) , FATE Fate Therapeutics $41.65 / +2.01 (+5.07%) , LLY Eli Lilly $244.29 / +4.405 (+1.84%) , ZYME Zymeworks $7.87 / +0.25 (+3.28%) , TARA Protara Therapeutics $5.04 / +0.03 (+0.60%) , ONTX Onconova $1.74 / -0.05 (-2.79%) , XLO Xilio Therapeutics $10.43 / +0.1 (+0.97%) , MGNX MacroGenics $11.89 / +0.38 (+3.30%) , KYMR Kymera Therapeutics $42.77 / +1.21 (+2.91%) , SWTX SpringsWorks Therapeutics $55.25 / +2.14 (+4.03%) , VBLT VBL Therapeutics $1.32 / +0.03 (+2.33%) , MRUS Merus $25.34 / +0.1 (+0.40%) , SRRA Sierra Oncology $32.70 / +0.47 (+1.46%) , IGMS IGM Biosciences $18.00 / +0.77 (+4.47%) , RPTX Repare Therapeutics $15.68 / +0.73 (+4.88%) , ERAS Erasca $12.23 / +0.36 (+3.03%) , BLUE Bluebird Bio $7.24 / +0.21 (+2.99%) , RVMD Revolution Medicines $22.38 / +0.98 (+4.58%) , RAIN Rain Therapeutics $7.70 / +0.49 (+6.80%) Virtual Oncology… Virtual Oncology Conference to be held on February 9-11. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZYME XLO VBLT TNGX TARA SWTX SRRA RPTX RLAY RAIN PMVP ONTX MRUS MGNX LLY KYMR IMRX IGMS FATE ERAS DCPH BOLT BLUE ALLO ADCT ACET ZYME Zymeworks $7.87 / +0.25 (+3.28%) 01/27/22 Zymeworks falls -11.8% 01/20/22 Zymeworks falls -6.2% 01/19/22 Zymeworks outlines strategic priorities for 2022 and 2023; reduces workforce 01/12/22 Zymeworks Chief Medical Officer buys 5K shares of common stock XLO Xilio Therapeutics $10.43 / +0.1 (+0.97%) 01/20/22 Xilio Therapeutics initiates patient dosing in Phase 1/2 trial of XTX202 12/02/21 Xilio Therapeutics expects cash, cash equivalents to fund into 2024 12/02/21 Xilio Therapeutics announces anticipated milestones for 2022 11/12/21 Xilio Therapeutics announces preclinical data on XTX301 at SITC meeting VBLT VBL Therapeutics $1.32 / +0.03 (+2.33%) 01/18/22 VBL Therapeutics appoints Matthew Trudeau as CCO 12/20/21 VBL Therapeutics selected for EUR17.5M of funding from EIC Accelerator 11/15/21 VBL Therapeutics expects cash to fund operations into 4Q23 10/05/21 VBL Therapeutics appoints Sam Backenroth as CFO TNGX Tango Therapeutics $9.00 / + (+0.00%) 01/24/22 Tango Therapeutics announces clearance of TNG908 IND, pipeline progress 11/09/21 Tango Therapeutics expects cash to fund operations into 2H24 11/01/21 Tango Therapeutics appoints Marc Rudoltz as CMO, Doug Barry as general counsel 09/30/21 Tango Therapeutics to present preclinical data on at AACR-NCI-EORTC 2021 TARA Protara Therapeutics $5.04 / +0.03 (+0.60%) 01/10/22 Protara Therapeutics appoints Jathin Bandaria as CMO 10/12/21 Protara Therapeutics announces FDA clearance of IND for TARA-002 09/13/21 Protara announces results from study on cholestasis in patients on PN SWTX SpringsWorks Therapeutics $55.25 / +2.14 (+4.03%) 12/10/21 SpringsWorks Therapeutics announces trial collaboration with AbbVie 12/06/21 SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study 11/29/21 SpringsWorks Therapeutics announces full enrollment of Phase 2b ReNeu trial 10/27/21 SpringsWorks Therapeutics begins expanded Phase 2 for nirogacestat in myeloma SRRA Sierra Oncology $32.70 / +0.47 (+1.46%) 01/25/22 Sierra Oncology trading resumes 01/25/22 Sierra Oncology trading halted, news pending 01/25/22 Sierra provides update to support future commercialization of momelotinib 01/25/22 Sierra provides update to support future commercialization of momelotinib RPTX Repare Therapeutics $15.68 / +0.73 (+4.88%) 12/21/21 Repare Therapeutics doses 1st patient in RP-6306 combo trial with gemcitabine 10/08/21 Repare Therapeutics presents preliminary data from Phase 1/2 TRESR trial 10/07/21 Repare Therapeutics issues statement on inadvertent issuance of RP-3500 abstract 09/07/21 Repare Therapeutics appoints Thomas Civik as chairman RLAY Relay Therapeutics $21.64 / +0.78 (+3.74%) 01/27/22 Relay Therapeutics treatment of cholangiocarcinoma granted orphan designation 01/04/22 Relay first patient dosed in trial of RLY-2608, initiates RLY-4008 expansion 12/10/21 Relay Therapeutics announces preclinical data on RLY-2608 10/08/21 Relay Therapeutics trading resumes RAIN Rain Therapeutics $7.70 / +0.49 (+6.80%) 01/05/22 Rain Therapeutics, Roche to collaborate on trial of milademetan combination 12/14/21 Rain Therapeutics added to Nasdaq Biotechnology Index 11/19/21 Rain Therapeutics doses first patient in Phase 2 basket trial of milademetan PMVP PMV Pharmaceuticals $15.61 / +0.41 (+2.70%) 09/09/21 PMV Pharmaceuticals appoints Tim Smith as SVP, head of corporate development ONTX Onconova $1.74 / -0.05 (-2.79%) 12/02/21 Onconova presents preliminary data on rigosertib in RDEB-associated SCC 09/22/21 Onconova announces preliminary data from Phase 1/2a trial of oral rigosertib MRUS Merus $25.34 / +0.1 (+0.40%) 01/25/22 Merus names Shannon Campbell as Chief Commercial Officer 12/10/21 Merus presents updated analyst on zenocutuzumab combination study 12/02/21 Merus announces poster presentation on MCLA-145 at ESMO-IO 10/07/21 Merus presents early clinical data on MCLA-158, preclinical data on Zeno MGNX MacroGenics $11.89 / +0.38 (+3.30%) 01/10/22 Sesen Bio appoints Minori Rosales as chief development officer 12/27/21 I-Mab announces IND approval from China NMPA for Phase 2 trial of enoblituzumab 10/05/21 Zai Lab announces study of margetuximab in China met primary endpoint 09/28/21 I-Mab announces approval of phase 2 trial for enoblituzumab in China LLY Eli Lilly $244.29 / +4.405 (+1.84%) 02/08/22 Rain Therapeutics announces key appointments to leadership team 02/01/22 Veru enters into clinical trial collaboration, supply agreement with Eli Lilly 01/28/22 Eli Lilly reports $1B investment in new manufacturing facility in North Carolina 01/28/22 Eli Lilly reports $1B investment in new manufacturing facility in North Carolina KYMR Kymera Therapeutics $42.77 / +1.21 (+2.91%) 01/18/22 Kymera Therapeutics appoints John Maraganore to board of directors 01/10/22 Kymera Therapeutics announces 2022 goals, milestones 12/16/21 Kymera Therapeutics discloses new KT-474 clinical data 12/13/21 Kymera Therapeutics presents preclinical data on STAT3 degraders IMRX Immuneering $9.94 / -0.08 (-0.80%) 12/06/21 Immuneering Corporation (Class A Stock) trading resumes 12/06/21 Immuneering Corporation (Class A Stock) trading halted, volatility trading pause 09/20/21 Immuneering to be added to Russell 2000 Index IGMS IGM Biosciences $18.00 / +0.77 (+4.47%) 02/09/22 IGM Biosciences advances IGM-6268 into clinical trials to treat COVID-19 01/05/22 Icosavax appoints John Shiver to board of directors 12/12/21 IGM presents data from IGM-2323 in patients with Advanced B Cell Malignancies 12/08/21 IGM to collaborate on study of IgM, IgA antibodies to prevent malaria FATE Fate Therapeutics $41.65 / +2.01 (+5.07%) 01/10/22 Fate Therapeutics announces FDA clearance for FT536 12/14/21 Cathie Wood's ARK Investment bought 196K shares of Fate Therapeutics on Tuesday 12/13/21 Fate Therapeutics reports 'positive' interim Phase 1 data from FT596 program 12/13/21 Fate Therapeutics announces data from Phase 1 study of FT516 ERAS Erasca $12.23 / +0.36 (+3.03%) 01/18/22 Erasca appoints Tesvich-Bonora as CPO, promotes Shoemaker to SVP of Research 12/17/21 Erasca announces FDA clearance of IND application for ERAS-801 12/14/21 Erasca added to Nasdaq Biotechnology Index 09/22/21 Erasca announces first patient dosed in HERKULES-3 trial evaluating ERAS-007 DCPH Deciphera $8.89 / +0.75 (+9.21%) 01/24/22 Deciphera presents Phase 3 results of ripretinib in gastrointestinal tumor 01/11/22 Oryzon appoints Ana Limon as SVP, clinical development, global medical affairs 12/21/21 Deciphera says UK MHRA grants MA for Qinlock or ripretinib to treat GIST 11/30/21 Deciphera Pharmaceuticals trading resumes BOLT Bolt Biotherapeutics $3.35 / +0.04 (+1.21%) 01/06/22 Bolt doses first patient with BDC-1001 in combination with OPDIVO 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial 11/19/21 Bolt Biotherapeutics appoints Brian O'Callaghan, Frank Lee to board BLUE Bluebird Bio $7.24 / +0.21 (+2.99%) 01/18/22 Bluebird Bio falls after FDA extends review for biologics licensing applications 01/11/22 Bluebird Bio cash, cash and cash equivalents $442M at year-end 01/11/22 Bluebird Bio provides update on program milestones ALLO Allogene Therapeutics $11.12 / +0.32 (+2.96%) 01/14/22 Allogene Therapeutics director Belldegrun buys 155,039 common shares 01/11/22 Allogene Therapeutics announces collaboration license agreement with Antion 01/10/22 Allogene Therapeutics says FDA lifts hold on clinical trials 01/10/22 Allogene announces removal of FDA clinical hold across AlloCAR T trials ADCT ADC Therapeutics $16.70 / +0.4 (+2.45%) 01/18/22 ADC Therapeutics enters exclusive Zynlonta license agreement with MTPC 10/29/21 ADC Therapeutics announces validation of Zynlonta MAA by EMA 09/29/21 ADC Therapeutics joint venture doses first patient in Zynlonta study 09/27/21 ADC Therapeutics doses first patient in ADCT-901 trial ACET Adicet Bio $14.21 / +0.55 (+4.03%) 12/06/21 Adicet Bio trading resumes 12/06/21 Adicet Bio trading halted, volatility trading pause 12/06/21 Adicet Bio announces interim data from Phase 1 study of ADI-001 11/18/21 Adicet Bio appoints Michael Kauffman to board of directors ACET ADCT ALLO BOLT DCPH TNGX RLAY IMRX PMVP FATE LLY ZYME TARA ONTX XLO MGNX KYMR SWTX VBLT MRUS SRRA IGMS RPTX ERAS BLUE RVMD RAIN ACET Adicet Bio $14.21 / +0.55 (+4.03%) 01/03/22 Guggenheim ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim 12/06/21 BTIG Adicet Bio data highlights 'impressive' anti-tumor responses, says BTIG 12/06/21 Canaccord Canaccord remains bullish on Adicet after 'highly positive' interim ADI-001 data 12/06/21 Guggenheim Adicet Bio price target raised to $33 from $22 at Guggenheim ADCT ADC Therapeutics $16.70 / +0.4 (+2.45%) 02/01/22 Morgan Stanley ADC Therapeutics price target lowered to $29 from $47 at Morgan Stanley 11/08/21 Wolfe Research ADC Therapeutics initiated with an Outperform at Wolfe Research 09/07/21 Cantor Fitzgerald ADC Therapeutics selloff on CMO departure overdone, says Cantor Fitzgerald 08/09/21 RBC Capital ADC Therapeutics initiated with an Outperform at RBC Capital ALLO Allogene Therapeutics $11.12 / +0.32 (+2.96%) 01/10/22 Stifel Allogene ASH update may be weighing on shares despite holds lifted, says Stifel 01/06/22 Wells Fargo Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16 01/03/22 Guggenheim Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim 01/03/22 B. Riley iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022 BOLT Bolt Biotherapeutics $3.35 / +0.04 (+1.21%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 SVB Leerink Bolt Biotherapeutics initiated with an Outperform at SVB Leerink DCPH Deciphera $8.89 / +0.75 (+9.21%) 02/08/22 Piper Sandler Deciphera's Q4 update was in-line, says Piper Sandler 12/01/21 H.C. Wainwright Deciphera price target lowered to $15 from $25 at H.C. Wainwright 11/30/21 Piper Sandler Deciphera price target lowered to $11 from $14 at Piper Sandler 11/08/21 Barclays Deciphera downgraded to Equal Weight at Barclays after GIST trial miss TNGX Tango Therapeutics $9.00 / + (+0.00%) 09/20/21 SVB Leerink SVB Leerink bullish on Tango Therapeutics, initiates with an Outperform 09/20/21 SVB Leerink Tango Therapeutics initiated with an Outperform at SVB Leerink 09/07/21 Fly Intel: Top five analyst initiations 09/07/21 Wedbush Tango Therapeutics initiated with an Outperform at Wedbush RLAY Relay Therapeutics $21.64 / +0.78 (+3.74%) 02/01/22 Berenberg Relay Therapeutics initiated with a Buy at Berenberg 01/03/22 Guggenheim Relay Therapeutics price target lowered to $45 from $52 at Guggenheim 11/08/21 Jefferies Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts 08/17/21 H.C. Wainwright Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright IMRX Immuneering $9.94 / -0.08 (-0.80%) 01/07/22 Piper Sandler Immuneering initiated with an Overweight at Piper Sandler 01/03/22 Guggenheim Immuneering price target lowered to $30 from $42 at Guggenheim 08/24/21 Morgan Stanley Immuneering initiated with an Equal Weight at Morgan Stanley 08/24/21 Jefferies Immuneering initiated with a Buy at Jefferies PMVP PMV Pharmaceuticals $15.61 / +0.41 (+2.70%) 09/22/21 Goldman Sachs PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs 08/19/21 Oppenheimer PMV Pharmaceuticals initiated with a Perform at Oppenheimer 08/02/21 Guggenheim PMV Pharmaceuticals initiated with a Buy at Guggenheim 07/29/21 H.C. Wainwright PMV Pharmaceuticals initiated with a Buy at H.C. Wainwright FATE Fate Therapeutics $41.65 / +2.01 (+5.07%) 01/03/22 Guggenheim Fate Therapeutics price target lowered to $78 from $107 at Guggenheim 12/30/21 Mizuho Mizuho announces top oncology stock picks for 2022 12/15/21 Wedbush Wedbush upgrades Fate Therapeutics to Outperform, ups price target to $74 12/15/21 Wedbush Fate Therapeutics upgraded to Outperform from Neutral at Wedbush LLY Eli Lilly $244.29 / +4.405 (+1.84%) 02/04/22 Morgan Stanley Eli Lilly price target lowered to $265 from $272 at Morgan Stanley 02/04/22 Mizuho Eli Lilly changes to Alzheimer's strategy make sense, says Mizuho 02/03/22 Truist Eli Lilly thinks final Alzheimer's NCD 'may not change very much,' says Truist 01/21/22 DZ Bank Eli Lilly upgraded to Buy from Hold at DZ Bank ZYME Zymeworks $7.87 / +0.25 (+3.28%) 02/09/22 Wells Fargo Zymeworks price target lowered to $45 from $56 at Wells Fargo 12/10/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James 12/10/21 SVB Leerink Zymeworks upgraded to Outperform from Market Perform at SVB Leerink 12/09/21 Raymond James Zymeworks downgraded to Outperform from Strong Buy at Raymond James TARA Protara Therapeutics $5.04 / +0.03 (+0.60%) 06/04/21 H.C. Wainwright Protara Therapeutics initiated with a Buy at H.C. Wainwright 04/26/21 Oppenheimer Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer ONTX Onconova $1.74 / -0.05 (-2.79%) 09/28/21 Guggenheim Onconova price target lowered to $12 from $29 at Guggenheim 05/18/21 Guggenheim Onconova initiated with a Buy at Guggenheim XLO Xilio Therapeutics $10.43 / +0.1 (+0.97%) 01/10/22 H.C. Wainwright Xilio Therapeutics initiated with a Buy at H.C. Wainwright 11/16/21 Morgan Stanley Xilio Therapeutics initiated with an Overweight at Morgan Stanley 11/16/21 Raymond James Xilio Therapeutics initiated with an Outperform at Raymond James 11/16/21 Guggenheim Xilio Therapeutics initiated with a Buy at Guggenheim MGNX MacroGenics $11.89 / +0.38 (+3.30%) 02/03/22 SMBC Nikko MacroGenics initiated with an Outperform at SMBC Nikko 11/17/21 Guggenheim MacroGenics assumed with a Buy at Guggenheim 10/19/21 JMP Securities MacroGenics initiated with an Outperform at JMP Securities 10/14/21 BTIG MacroGenics assumed with a Buy at BTIG KYMR Kymera Therapeutics $42.77 / +1.21 (+2.91%) 01/03/22 Piper Sandler Piper names Kymera Therapeutics a top pick for 2022, ups target 10/13/21 Brookline Kymera Therapeutics initiated with Buy, $80 target at Brookline 10/12/21 Brookline Kymera Therapeutics initiated with a Buy at Brookline SWTX SpringsWorks Therapeutics $55.25 / +2.14 (+4.03%) 10/27/21 Wedbush Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data 09/08/21 JPMorgan SpringsWorks price target raised to $105 from $97 at JPMorgan 07/21/21 H.C. Wainwright SpringsWorks price target raised to $136 from $124 at H.C. Wainwright 07/20/21 Goldman Sachs SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs VBLT VBL Therapeutics $1.32 / +0.03 (+2.33%) 08/30/21 Roth Capital Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes 06/15/21 Roth Capital Roth does not see material change to VBL readout timelines 06/03/21 Roth Capital Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update 05/18/21 Guggenheim VBL Therapeutics initiated with a Buy at Guggenheim MRUS Merus $25.34 / +0.1 (+0.40%) 11/17/21 Fly Intel: Top five analyst initiations 11/17/21 Guggenheim Merus assumed with a Buy at Guggenheim 11/12/21 H.C. Wainwright Merus price target raised to $45 from $30 at H.C. Wainwright SRRA Sierra Oncology $32.70 / +0.47 (+1.46%) 01/31/22 H.C. Wainwright Sierra Oncology price target raised to $51 from $35 at H.C. Wainwright 01/27/22 Oppenheimer Sierra Oncology price target raised to $38 from $32 at Oppenheimer 11/30/21 Cantor Fitzgerald Sierra Oncology price target raised to $39 from $33 at Cantor Fitzgerald 11/05/21 H.C. Wainwright Sierra Oncology price target raised to $35 from $29 at H.C. Wainwright IGMS IGM Biosciences $18.00 / +0.77 (+4.47%) 01/03/22 Guggenheim IGM Biosciences price target lowered to $55 from $100 at Guggenheim 12/16/21 H.C. Wainwright IGM Biosciences price target lowered to $76 from $114 at H.C. Wainwright 12/14/21 Baird IGM Biosciences price target lowered to $65 from $90 at Baird 12/13/21 Morgan Stanley Morgan Stanley cuts IGM Biosciences as lack of dose response raises concerns RPTX Repare Therapeutics $15.68 / +0.73 (+4.88%) 11/18/21 Northland Repare Therapeutics price target raised to $45 from $40 at Northland 11/10/21 Stifel Stifel trims Repare Therapeutics price target to $47 after 'quiet' Q3 report 09/22/21 Stifel Repare Therapeutics initiated with a Buy at Stifel 09/13/21 H.C. Wainwright Repare Therapeutics initiated with a Buy at H.C. Wainwright ERAS Erasca $12.23 / +0.36 (+3.03%) 01/03/22 Guggenheim Erasca price target lowered to $20 from $25 at Guggenheim 08/10/21 Fly Intel: Top five analyst initiations 08/10/21 Evercore ISI Erasca initiated with an Outperform at Evercore ISI 08/10/21 JPMorgan Erasca initiated with an Overweight at JPMorgan BLUE Bluebird Bio $7.24 / +0.21 (+2.99%) 01/05/22 Wells Fargo Avrobio price target lowered to $8 from $36 at Wells Fargo 12/06/21 Cowen Cowen starts Crispr at Market Perform as applications 'need maturing' 11/12/21 BMO Capital Bluebird Bio price target lowered to $13 from $21 at BMO Capital 11/08/21 Canaccord 2seventy Bio initiated with a Buy at Canaccord RVMD Revolution Medicines $22.38 / +0.98 (+4.58%) 11/12/21 H.C. Wainwright Revolution Medicines price target raised to $38 from $31 at H.C. Wainwright 09/22/21 Stifel Revolution Medicines initiated with a Hold at Stifel 08/17/21 H.C. Wainwright Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright 08/12/21 Fly Intel: Top five analyst downgrades RAIN Rain Therapeutics $7.70 / +0.49 (+6.80%) 01/03/22 Guggenheim Rain Therapeutics price target lowered to $20 from $26 at Guggenheim 11/10/21 Piper Sandler Rain Therapeutics price target raised to $26 from $25 at Piper Sandler 09/14/21 Fly Intel: Top five analyst downgrades 09/14/21 Goldman Sachs Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs ZYME XLO VBLT TNGX TARA SWTX SRRA RVMD RPTX RLAY RAIN PMVP MRUS MGNX LLY KYMR IMRX IGMS FATE ERAS DCPH BOLT BLUE ALLO ADCT ACET ZYME Zymeworks $7.87 / +0.25 (+3.28%) 11/03/21 Zymeworks reports Q3 EPS ($1.25), consensus ($1.17) XLO Xilio Therapeutics $10.43 / +0.1 (+0.97%) 12/02/21 Xilio Therapeutics reports Q3 EPS ($21.27), four estimates ($1.60) VBLT VBL Therapeutics $1.32 / +0.03 (+2.33%) 11/15/21 VBL Therapeutics reports Q3 EPS (9c), consensus (11c) 08/16/21 VBL Therapeutics reports Q2 EPS (12c), consensus (11c) TNGX Tango Therapeutics $9.00 / + (+0.00%) 11/09/21 Tango Therapeutics reports Q3 EPS (28c), consensus (28c) TARA Protara Therapeutics $5.04 / +0.03 (+0.60%) 11/04/21 Protara Therapeutics reports Q3 EPS (96c), three estimates ($1.01) SWTX SpringsWorks Therapeutics $55.25 / +2.14 (+4.03%) 11/04/21 SpringsWorks Therapeutics reports Q3 EPS (84c), consensus (76c) SRRA Sierra Oncology $32.70 / +0.47 (+1.46%) 11/05/21 Sierra Oncology reports Q3 adjusted EPS ($1.86), consensus ($1.78) RVMD Revolution Medicines $22.38 / +0.98 (+4.58%) 11/10/21 Revolution Medicines sees FY21 GAAP net loss $170M-$190M 11/10/21 Revolution Medicines reports Q3 EPS (72c), consensus (62c) 08/11/21 Revolution Medicines reports Q2 EPS (60c), consensus (48c) RPTX Repare Therapeutics $15.68 / +0.73 (+4.88%) 11/10/21 Repare Therapeutics reports Q3 EPS (83c), consensus (71c) 11/10/21 Repare Therapeutics reports Q3 EPS (83c), consensus (71c) 08/12/21 Repare Therapeutics reports Q2 EPS (71c), consensus (60c) RLAY Relay Therapeutics $21.64 / +0.78 (+3.74%) 11/10/21 Relay Therapeutics reports Q3 EPS (66c), consensus (64c) 08/12/21 Relay Therapeutics reports Q2 EPS ($2.10), consensus (45c) RAIN Rain Therapeutics $7.70 / +0.49 (+6.80%) 11/10/21 Rain Therapeutics reports Q3 EPS (70c), consensus (48c) 08/10/21 Rain Therapeutics reports Q2 EPS (39c), consensus (60c) PMVP PMV Pharmaceuticals $15.61 / +0.41 (+2.70%) 11/12/21 PMV Pharmaceuticals reports Q3 EPS (33c), consensus (30c) 08/13/21 PMV Pharmaceuticals reports Q2 EPS (29c), consensus (27c) MRUS Merus $25.34 / +0.1 (+0.40%) 11/02/21 Merus reports Q3 EPS (39c), consensus (68c) MGNX MacroGenics $11.89 / +0.38 (+3.30%) 11/02/21 MacroGenics reports Q3 EPS (86c), consensus (69c) LLY Eli Lilly $244.29 / +4.405 (+1.84%) 02/03/22 Eli Lilly backs FY22 EPS view $8.50-$8.65, consensus $7.54 02/03/22 Eli Lilly reports Q4 EPS $2.49, consensus $2.18 02/02/22 Notable companies reporting before tomorrow's open KYMR Kymera Therapeutics $42.77 / +1.21 (+2.91%) 11/10/21 Kymera Therapeutics reports Q3 EPS (56c), consensus (42c) IMRX Immuneering $9.94 / -0.08 (-0.80%) 11/09/21 Immuneering reports Q3 EPS (47c), consensus (57c) IGMS IGM Biosciences $18.00 / +0.77 (+4.47%) 11/04/21 IGM Biosciences reports Q3 EPS ($1.32), consensus ($1.37) 08/09/21 IGM Biosciences reports Q2 EPS ($1.16), consensus ($1.17) FATE Fate Therapeutics $41.65 / +2.01 (+5.07%) 11/04/21 Fate Therapeutics reports Q3 EPS (45c), consensus (58c) ERAS Erasca $12.23 / +0.36 (+3.03%) 11/10/21 Erasca reports Q3 EPS (46c), consensus (32c) DCPH Deciphera $8.89 / +0.75 (+9.21%) 02/08/22 Deciphera reports Q4 EPS ($1.51), consensus ($1.33) 11/02/21 Deciphera Pharmaceuticals reports Q3 EPS ($1.37), consensus ($1.28) BOLT Bolt Biotherapeutics $3.35 / +0.04 (+1.21%) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) 08/12/21 Bolt Biotherapeutics reports Q2 EPS (64c), consensus (43c) BLUE Bluebird Bio $7.24 / +0.21 (+2.99%) 11/05/21 Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60) 11/05/21 Bluebird Bio reports Q3 EPS ($3.16), consensus ($2.60) ALLO Allogene Therapeutics $11.12 / +0.32 (+2.96%) 11/04/21 Allogene Therapeutics reports Q3 EPS (57c), consensus (56c) ADCT ADC Therapeutics $16.70 / +0.4 (+2.45%) 11/02/21 ADC Therapeutics reports Q3 adjusted EPS (59c), consensus (92c) ACET Adicet Bio $14.21 / +0.55 (+4.03%) 11/10/21 Adicet Bio reports Q3 EPS (44c), consensus (44c) 08/12/21 Adicet Bio reports Q2 EPS (34c), consensus (53c) 27 Jan 27 Jan 08 Dec 05 Nov 28 Oct 22 Oct 13 Oct 24 Sep 30 Jul 16 Jul 01 Jul 23 Apr 09 Apr 02 Mar 11 Feb 10 Feb ZYME LLY ZYME Zymeworks $7.87 / +0.25 (+3.28%) 09/17/21 Zymeworks data 'could intensify potential sale talks,' Dealreporter says LLY Eli Lilly $244.29 / +4.405 (+1.84%) 01/25/22 White House limits use of Regeneron, Lilly Covid-19 antibody drugs, WSJ reports 12/22/21 Most monoclonal antibody treatments failing against omicron, NY Times reports 12/03/21 FDA planning fast review of omicron vaccines and drugs, WSJ reports 11/30/21 COVID-19 antibody drugs struggle with omnicron, WSJ reports ZYME XLO TARA SRRA RLAY ONTX MRUS MGNX LLY IMRX IGMS FATE DCPH BOLT BLUE ALLO ACET ZYME Zymeworks $7.87 / +0.25 (+3.28%) 09/17/21 Wall Street in Fives - Must Read Lists for Friday 09/17/21 Wall Street in Fives - Must Read Lists at Midday XLO Xilio Therapeutics $10.43 / +0.1 (+0.97%) 10/23/21 Opening Day: Portillo's jumps in debut as Vita Coco falls short of IPO goals TARA Protara Therapeutics $5.04 / +0.03 (+0.60%) 01/03/22 Fly Insider: Ashford, Coinbase among week's notable insider trades SRRA Sierra Oncology $32.70 / +0.47 (+1.46%) 02/07/22 Fly Insider: Kodiak, Accenture among week's notable insider trades RLAY Relay Therapeutics $21.64 / +0.78 (+3.74%) 10/12/21 Fly Intel: Pre-market Movers 10/11/21 Fly Intel: After-Hours Movers 08/12/21 Fly Intel: After-Hours Movers ONTX Onconova $1.74 / -0.05 (-2.79%) 09/23/21 Fly Intel: After-Hours Movers MRUS Merus $25.34 / +0.1 (+0.40%) 10/07/21 Wall Street in Fives - Must Read Lists for Thursday 10/07/21 Wall Street in Fives - Must Read Lists at Midday MGNX MacroGenics $11.89 / +0.38 (+3.30%) 09/16/21 Wall Street in Fives - Must Read Lists for Thursday 09/16/21 Wall Street in Fives - Must Read Lists at Midday 09/07/21 Fly Intel: After-Hours Movers LLY Eli Lilly $244.29 / +4.405 (+1.84%) 02/03/22 Wall Street in Fives - Must Read Lists for Thursday 02/03/22 Wall Street in Fives - Must Read Lists at Midday 01/28/22 Wall Street in Fives - Must Read Lists for Friday 01/13/22 Meet Prothena: Fly exclusive interview with CEO Gene Kinney IMRX Immuneering $9.94 / -0.08 (-0.80%) 08/21/21 Opening Day: Sportradar files for IPO after SPAC talks break off IGMS IGM Biosciences $18.00 / +0.77 (+4.47%) 12/13/21 Wall Street in Fives - Must Read Lists for Monday 12/13/21 Wall Street in Fives - Must Read Lists at Midday 12/13/21 Fly Intel: Pre-market Movers FATE Fate Therapeutics $41.65 / +2.01 (+5.07%) 08/20/21 Wall Street in Fives - Must Read Lists for Friday 08/20/21 Wall Street in Fives - Must Read Lists at Midday 08/19/21 Fly Intel: After-Hours Movers DCPH Deciphera $8.89 / +0.75 (+9.21%) 11/08/21 Wall Street in Fives - Must Read Lists for Monday 11/08/21 Wall Street in Fives - Must Read Lists at Midday 11/05/21 Wall Street in Fives - Must Read Lists for Friday 11/05/21 Wall Street in Fives - Must Read Lists at Midday BOLT Bolt Biotherapeutics $3.35 / +0.04 (+1.21%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce BLUE Bluebird Bio $7.24 / +0.21 (+2.99%) 01/18/22 Fly Intel: Wall Street's top stories for Tuesday 01/11/22 Fly Intel: Pre-market Movers 12/20/21 Wall Street in Fives - Must Read Lists for Monday 12/20/21 Wall Street in Fives - Must Read Lists at Midday ALLO Allogene Therapeutics $11.12 / +0.32 (+2.96%) 01/10/22 Wall Street in Fives - Must Read Lists for Monday 01/10/22 Wall Street in Fives - Must Read Lists at Midday 10/08/21 Wall Street in Fives - Must Read Lists for Friday 10/08/21 Wall Street in Fives - Must Read Lists at Midday ACET Adicet Bio $14.21 / +0.55 (+4.03%) 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 02/11/22 Virtual Oncology Conference 02/18/22 ASCO Genitourinary Cancers Symposium 2022 03/08/22 42nd Annual Healthcare Conference 06/03/22 2022 ASCO Annual Meeting 02/24/22 Zymeworks - ZYME 04/28/22 Eli Lilly - LLY 08/19/22 PDUFA Date for betibeglogene autotemcel (beti-cel) 02/14/22 Eli Lilly 02/15/22 Eli Lilly SRRA LLY BLUE ALLO SRRA Sierra Oncology $32.70 / +0.47 (+1.46%) 02/02/22 Ten new option listings and three option delistings on February 2nd LLY Eli Lilly $244.29 / +4.405 (+1.84%) 12/15/21 Early notable gainers among liquid option names on December 15th 11/19/21 Early notable gainers among liquid option names on November 19th 11/17/21 Early notable gainers among liquid option names on November 17th BLUE Bluebird Bio $7.24 / +0.21 (+2.99%) 11/08/21 Two new option listings and two option delistings on November 8th 11/05/21 One new option listing and one option delisting on November 5th ALLO Allogene Therapeutics $11.12 / +0.32 (+2.96%) 10/14/21 Unusually active option classes on open October 14th
Hot Stocks	Bolt doses first patient with BDC-1001 in combination with OPDIVO » 08:14 01/06/22 01/06 08:14 01/06/22 08:14 BOLT Bolt Biotherapeutics $4.16 / -0.39 (-8.57%) , BMY Bristol-Myers $61.60 / +0.01 (+0.02%) Bolt Biotherapeutics… Bolt Biotherapeutics (BOLT) announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb's (BMY) PD-1 checkpoint inhibitor OPDIVO. BDC-1001 is a HER2-targeting Boltbody immune-stimulating antibody conjugate in development for the treatment of patients with HER2-expressing solid tumors. "We are excited to evaluate BDC-1001 in combination with nivolumab, a leading PD-1 checkpoint inhibitor. Pairing BDC-1001's mechanism of action with the checkpoint inhibitor approach has the potential to yield a stronger, targeted modulation of the immune system. Initial safety and early efficacy findings reported from the ongoing monotherapy arm of the Phase 1/2 clinical trial make BDC-1001 a potentially promising candidate for the treatment of patients with HER2-expressing solid tumors," said Edith Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options BOLT BMY BOLT Bolt Biotherapeutics $4.16 / -0.39 (-8.57%) 12/16/21 Bolt Biotherapeutics appoints Nicole Onetto to board of directors 12/06/21 Bolt Biotherapeutics reports interim data from BDC-1001 Phase 1/2 trial 11/19/21 Bolt Biotherapeutics appoints Brian O'Callaghan, Frank Lee to board 11/12/21 Bolt Biotherapeutics presents new preclinical data from three programs BMY Bristol-Myers $61.60 / +0.01 (+0.02%) 01/05/22 Biohaven Pharmaceutical, Pfizer complete rimegepant, zavegepant collaboration 12/15/21 Bristol-Myers confirms FDA approves Orencia combo for prevention of aGvHD 12/15/21 Bristol-Myers acute graft versus host disease drug gets FDA approval 12/14/21 Immatics and Bristol-Myers enter into an agreement for IMA401 BOLT BMY BOLT Bolt Biotherapeutics $4.16 / -0.39 (-8.57%) 01/06/22 Morgan Stanley Bolt Biotherapeutics downgraded to Equal Weight from Overweight at Morgan Stanley 12/06/21 Stifel Bolt Biotherapeutics price target lowered to $19 from $34 at Stifel 03/02/21 Fly Intel: Top five analyst initiations 03/02/21 SVB Leerink Bolt Biotherapeutics initiated with an Outperform at SVB Leerink BMY Bristol-Myers $61.60 / +0.01 (+0.02%) 01/03/22 Piper Sandler Legend Biotech named a top pick for 2022 at Piper Sandler 12/21/21 Oppenheimer Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential 12/21/21 Piper Sandler Legend Biotech initiated with an Overweight at Piper Sandler 12/20/21 JPMorgan Bristol-Myers shares should rebound into 2022, says JPMorgan BOLT BMY BOLT Bolt Biotherapeutics $4.16 / -0.39 (-8.57%) 11/09/21 Bolt Biotherapeutics reports Q3 EPS (63c), consensus (65c) 08/12/21 Bolt Biotherapeutics reports Q2 EPS (64c), consensus (43c) BMY Bristol-Myers $61.60 / +0.01 (+0.02%) 10/27/21 Acceleron expects Q3 royalty revenue of approximately $32M from Reblozy 10/27/21 Bristol-Myers narrows FY21 non-GAAP EPS view to $7.40-$7.55 from $7.35-$7.55 10/27/21 Bristol-Myers reports Q3 EPS $2.00, consensus $1.92 10/26/21 Notable companies reporting before tomorrow's open 05 Feb BMY BMY Bristol-Myers $61.60 / +0.01 (+0.02%) 12/04/21 Bristol stock too cheap, could be ready to rally, Barron's says 11/18/21 J&J expects to file for approval of 14 new drugs by 2025, Reuters reports 11/12/21 Biden to nominate Robert Califf to lead FDA, Politico reports 11/03/21 Democrats reach agreement to lower prescription prices, WSJ reports BOLT BMY BOLT Bolt Biotherapeutics $4.16 / -0.39 (-8.57%) 12/10/21 Short Report: Bets against Stitch Fix spike as outlook falters 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday 11/12/21 Short Report: Bears not frightened by Bed Bath & Beyond bounce BMY Bristol-Myers $61.60 / +0.01 (+0.02%) 12/13/21 Wall Street in Fives - Must Read Lists for Monday 12/13/21 Wall Street in Fives - Must Read Lists at Midday 10/25/21 Wall Street in Fives - Must Read Lists for Monday 10/25/21 Wall Street in Fives - Must Read Lists at Midday 01/13/22 40th Annual Healthcare Virtual Conference 01/21/22 ASCO Gastrointestinal Cancers Symposium 06/03/22 2022 ASCO Annual Meeting 01/28/22 PDUFA Date for Mavacamten 03/19/22 PDUFA Date Relatlimab & Nivolumab 03/27/22 PDUFA Date for Reblozyl 04/28/22 Extended PDUFA Date for Mavacamten 05/28/22 PDUFA Date for Opdivo (Nivolumab) With Yervoy (Ipilimumab) 05/28/22 Opdivo with Fluoropyrimidine- and platinum-containing chemotherapy 09/10/22 PDUFA Date for Deucravacitinib (POETYK PSO-2) BMY BMY Bristol-Myers $61.60 / +0.01 (+0.02%) 12/15/21 Bristol Myers Squibb call volume above normal and directionally bullish 12/13/21 Early notable gainers among liquid option names on December 13th 10/01/21 Bristol Myers Squibb call volume above normal and directionally bullish 08/16/21 Bristol Myers Squibb call volume above normal and directionally bullish

16:26	What You Missed On Wall Street On Friday»
15:58	Bet On It: Kansas legalizes sports betting, aims to launch early»
13:59	Proven algorithm says sell these stocks now»
12:05	What You Missed On Wall Street This Morning»
09:59	Here's What You Missed in Crypto This Week»

	23rd Annual Financial Institutions Conference
	Regional Tech Virtual Conference
APD ...	Growth Discovery Virtual Conference
	17th Annual Technology & Media Virtual Conference
	Virtual Insurance Week
MCW	Mister Car Wash
PPG	PPG
ATNX	Athenex
ALC	Alcon
WE	WeWork

Get Full Fly Access